European Neuropsychopharmacology (v.13, #S4)
P.3.008 Weight gain during long-term drug treatment of obsessive-compulsive disorder by G. Maina; V. Salvi; U. Albert; F. Bogetto (S357).
P.3.007 Photosensitivity and affective disorders: Relationship with anxiety symptomatology by M. Martinucci; L. Bossini; A. De Capua; K. Paolini; P. Castrogiovanni (S356-S357).
P.3.009 Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs by U. Albert; G. Maina; F. Forner; F. Bogetto (S357-S358).
P.3.010 Stimulation of 5-HT neurons in the dorsal raphe nucleus inhibits panic-like behavior in rats by activation of 5-HT1A receptors in the dorsal periaqueductal gray by H. Zangrossi; R. Pobbe (S358).
P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder by E. Maron; J.T. Kuikka; J. Shlik; V. Vasar; E. Vanninen; J. Tiihonen (S358-S359).
P.3.006 Effects of cannabidiol (CBD) on regional cerebral blood flow by A. Zuardi; J.A. Crippa; G.E. Garrido; L. Wichter-Ana; R. Guarnieri; L. Ferrari; P.M. Marques; J.E.C. Hallak; P.K. Mc Guire; G.F. Busato (S356).
P.3.005 The aversive effect of a glutamate metabotropic receptor agonist injected into the dorsal periaqueductal grey may partially depend on glutamate release by F.S. Guimaraes; M.L. Molchanov (S355).
P.3.001 Increased hypothalamic-pituitary adrenal axis activity in children with anxiety disorders and matched controls by D. Van West; S. Claes; J. Sulon; D. Deboutte (S353-S354).
P.3.002 Megestrol attenuates hormonal response to CCK-4 by T. Raedler; H. Jahn; B. Goedecken; D.M. Gescher; M. Kellner; K. Widemann (S354).
P.3.003 Sensitivity to carbon dioxide in subjects with a single lifetime panic attack by E. Berzak; M. Reznik; O. Narsia; J. Benjamin (S354).
P.3.004 Role of glutamate-mediated neurotransmission in the medial hypothalamus on anxiety by F.S. Guimaraes; M.C. Jardim (S355).
P.3.012 Effect of the cortisol synthesis inhibitor, metyrapone, on anxiety before and after carbon dioxide challenge in panic disorder by L. Knyazhansky; U. Loewenthal; J. Arbelle; H. Cohen; A. Belgorodsky; J. Benjamin (S359).
P.3.013 The antiepileptic drug levetiracetam prevents bicuculline-indeed elevation in corticosterone levels and anxiety in the rat by Y. Lamberty; A.J. Gower; U. Falter; E. Wülfert; R. Grimée (S359).
P.3.020 A screen for genes induced in the amygdaloid area of rats during cat odor exposure by S. Koks (S362).
P.3.021 Selective AMPA receptor antagonist GYKI 52466 is effective in three animal models of anxiety by G. Kapus; I. Gacsályi; M. Vegh; G. Lévay (S362).
P.3.022 Role of GABA/benzodiazepine receptors of the dorsal periaqueductal grey of rats in the mediation of innate and conditioned anxiety responses by M. De Barros Viana; C. Bueno; H. Zangrossi (S362-S363).
P.3.023 A double-blind, placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder by H.G.M. Westenberg; D.J. Stein; H. Yang; D. Li; L.M. Barbato (S363).
P.3.019 Differences in beta-adrenergic receptor sensitivity between female and male with panic disorder by Y.R. Kim; S.K. Min; B.H. Yu (S361-S362).
P.3.018 Decreased TNF-α, IL-6, and NK activity in obsessive-compulsive disorder by D. Denys; S. Fluitman; A. Kavelaars; C. Heijnen; H.G.M. Westenberg (S361).
P.3.014 Stress increases susceptibility to oxidative damage in an experimental model of colitis in rats by J.C. Leza; A. Colón; J.L.M. Madrigal; L. Menchén; O. Hurtado; M.A. Moro; I. Lizasoain; J.C. Leza; P. Lorenzo (S359-S360).
P.3.015 Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide by J. Arlt; H. Jahn; M. Kellner; K. Wiedemann (S360).
P.3.016 The antiepileptic drug levetiracetam displays an anxiolytic profile in the potentiated startle paradigm in the rat by Y. Lamberty; S. Green; A. Vale; A.J. Gower; H. Klitgaard (S360-S361).
P.3.017 A double-blind, randomized, placebo-controlled trial of quetiapine augmentation in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitors by D. Denys; F. De Geus; H. Van Megen; H.G.M. Westenberg (S361).
P.2.169 Amygdala volume abnormalities in chronic schizophrenia by K. Kucharska-Pietura; P. Shaw; T. Russell; M.L. Phillips; A.S. David (S353).
P.2.167 Predictive factors associated to clinical outcome in schizophrenic patients treated with clozapine by M.C. Mauri; L.S. Volonteri; A. Fiorentini; G. Cerveri; S. Beraldo; M.L. Baldi; G. Panza; S. Bareggi (S353).
P.2.151 Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's dementia by P.P. De Deyn; M.M. Carrasco; W. Deberdt; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier (S345).
P.2.150 Ziprasidone in adjunctive treatment of acute bipolar mania: A randomized, double-blind placebo-controlled trial by R.H. Weisler; J. Dunn; P. English (S344-S345).
P.2.152 Ziprasidone in mania: A 21-day randomized, double-blind, placebo controlled trial by S. Segal; R.A. Riesenberg; K. Ice; P. English (S345-S346).
P.2.153 Typical-to-atypical versus atypical-to-typical antipsychotic switching strategies and visual evoked potentials (VEPs) in paranoid schizophrenia by B. Loza; I. Mazurek; A. Lecyk; M. Skaza (S346).
P.2.154 Quality of life and health status of previously untreated schizophrenic patients over the first 6 months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study by I. Gasquet; J.M. Haro; D. Novick; P. Frewer; S. Tzivelekis; S. Tcherny-Lessenot (S346-S347).
P.2.149 Motivational deficits: A comparison of olanzapine vs. haloperidol utilizing Bell's negative factor analysis by D.J. Walker; S. Ahmed; J.S. Kennedy; S.R. Lindborg; A. Breier (S344).
P.2.148 Dissociation of amygdala and visual cortex sensitivity for unpleasant facial expression in first-episode schizophrenic patients: An fMRI study by R. Strous; M. Bleich; R. Even; H. Harari; P. Pianka; P. Rotshtein; M. Kotler; T. Hendler (S343-S344).
P.2.143 Extrapyramidal symptoms after six months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study by P. Wright; J.M. Haro; P. Frewer; D. Novick; E.T. Edgell (S341-S342).
P.2.144 Oxidative stress in patients suffering from schizophrenia by N. Petronijevic; D. Marinkovic; D.V. Micic; B. Djuricic; V.R. Paunovic (S342).
P.2.145 The effectiveness of olanzapine versus plasma in maintaining the quality of life in stabilized patients with schizophrenia by C.M. Beasley; D.J. Walker; V.K. Sutton; K. Alaka; D. Naber; M. Namjoshi (S342-S343).
P.2.146 Inner speech and self-monitoring, the importance of external stimuli by J.P. Maes; J. Hulselmans (S343).
P.2.155 Treatment-induced changes in factor structure of schizophrenia after switching from typical to atypical antipsychotics by A. Lecyk; B. Loza; I. Mazurek (S347).
P.2.156 Atypical versus typical antipsychotic treatment prognosis based on VEPs and WCST scores in paranoid schizophrenia by I. Mazurek; B. Loza; A. Lecyk (S347-S348).
P.2.163 Sexual side effects of novel antipsychotics by S. Kesebir; B. Veznedaroglu; S. Pyryldar; B. Kayahan (S351).
P.2.164 Less weight gain with amisulpride: Results from double-blind studies vs. risperidone and olanzapine by J. Peuskens (S351).
P.2.165 Viral infection and neurodevelopmental (animal) model of schizophrenia: Effects of antipsychotics by H. Tejkalová; F. Št'astný; J. Klaschka (S351-S352).
P.2.166 The effects of atypical antipsychotics on the apomorphine-induced aggressiveness and quipazine-induced wet dog shakes in rats by R. Rudissaar; K. Pruus; V. Matto; L. Allikmets (S352).
P.2.162 Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: Interim results of a randomised, rater-blinded study by E. Sacchetti; P. Valsecchi; C. Regini; A. Galluzzo; P. Cacciani; E. Agrimi; C. Mencacci (S350-S351).
P.2.161 Risperidone olanzapine drug outcomes studies in schizophrenia (rodos). Final results based on 5734 schizophrenia patients by T.Y. Jun; D. Rosillon; I. Adriaenssen; I. Duchesne (S350).
P.2.157 Metabolic effects of long term treatment with depot neuroleptics and clozapine in patients with schizophrenia by J. Libiger; J. Krabec; D. Kalnicka; I. Tuma (S348).
P.2.158 Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia by M. Tuma; Z. Lenderova; M. Zemanova; E. Kadlecova; M. Pérez (S348-S349).
P.2.159 Long term treatment of chronic schizophrenia with risperidone by A. Karastergiou; A. Kanistras; G. Papadam; D. Kontis; A. Fotopoulos (S349).
P.2.160 Combination treatment with risperidone and diazepam in drug-naive schizophrenic patients by V.P. Kontaxakis; B.J. Havaki-Kontaxaki; S.S. Stamouli; G.N. Christodoulou (S349).
P.3.024 Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse by D.J. Stein; B. Van der Kolk; C. Austin; R. Fayyad; C. Clary (S363-S364).
P.3.025 Relapse prevention by escitalopram treatment of patients with social anxiety disorder (SAD) by S.A. Montgomery; N. Dürr-Pal; H. Loft; R. Nil (S364).
P.3.058 Venlafaxine XR and paroxetine in the short-term treatment of panic disorder by U. Lepola; M. Pollack; G. Emilien; E. Tzanis; T. Whitaker (S378).
P.3.057 Treatment of panick disorder with venlafaxine XR by A. Ahokas; J. Bradwejn; G. Emilien; T. Whitaker (S377-S378).
P.3.059 The reinstatement of conflict reverses the one-trial tolerance to diazepam on elevated plus-maze by R. Andreatini; M.A.B.F. Vital; G.L. Santos (S378-S379).
P.3.060 Efficacy of sertraline in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) by A. Ravindran; A.A. Dahl; C. Allgulander; T. Burt (S379).
P.3.061 A meta-analysis of the acute effect of buspirone on elevated plus-maze: A preliminary report by R. Andreatini; M.N. Souza; R. Boerngen-Lacerda (S379-S380).
P.3.056 Pregabalin in generalized anxiety disorder: Influence of subsyndromic depression by M. Pollack (S377).
P.3.055 Efficacy of pregablin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) by B. Lydiard (S377).
P.3.051 Efficacy of sertraline for the acute treatment of generalized anxiety disorder (GAD) by P.L.P. Morris; A.A. Dahl; S.P. Kutcher; J.A. Sogaard; C. Allgulander; T. Burt (S375).
P.3.052 Paroxetine improves the functional disability associated with mood and anxiety disorders by D. Sheehan; J. Christie; E. Dubé (S375).
P.3.053 Primary anxiety disorders: Impact of treatment on subsequent depression and health outcomes by L. Russo; J. Alonso; H. Bryson; R. Kessler; J.P. Lépine; J.M. Haro; V. Kovess; K. Demyttenaere; I. Gasquet; G. De Girolamo; S. Katz; M. Angermeyer; R. De Graaf; H. Ormel; G. Polidori; T. Brugha; P. Richetta (S376).
P.3.054 Pregabalin in generalized anxiety disorder: Speed of onset by S.A. Montgomery (S376-S377).
P.3.062 Venlafaxine XR and sertraline in PTSD: A placebo-controlled study by J.R.T. Davidson; A. Lipschitz; J. Musgnung (S380).
P.3.063 Long-term treatment of generalized social anxiety disorder with venlafaxine XR by D. Hackett; M.B. Stein; R. Mangano; M. Pollack (S380-S381).
P.3.070 CCK2 receptor deficient mice: Changes in anxiety and pain sensitivity by E. Vasar; S. Koks; U. Abramov; J. Innos; S. Raud; K. Kurrikoff; V. Volke; M. Bourin; T. Matsui (S384).
P.3.071 Paroxetine improves somatic symptoms associated with panic disorder and GAD by D.J. Stein; J. Christie; D. Duff (S384-S385).
P.3.072 SB-616234-A — a novel, potent and selective 5-HT1B receptor antagonist by J. Watson; C. Scott; C.J. Langmead; P. Wyman; P.W. Smith; L.A. Dawson; G.W. Price (S385).
P.3.073 The novel and selective 5-HT1B receptor antagonist SB-616234-A increases extracellular 5-HT and displays anxiolytic efficacy in guinea pigs by Z.A. Hughes; L. Bettelini; B. Trail; R. Arban; L.A. Dawson (S385-S386).
P.3.069 Placebo response and anxiety disorders: A critical evaluation of influential variables by C.S. Wilcox; B.B. Katz; J.F. Heiser; F.E. Cho; J.L. Morrissey; D.E. Grosz; A.I. Hardy; D.F. DeFrancisco (S383-S384).
P.3.068 Regional gray matter density and correlates of disease severity in panic disorder by G. Massana; P. Salgado-Pineda; J.M. Serra-Grabulosa; C. Gastó; C. Junqué; J. Massana; J.M. Mercader (S383).
P.3.064 Efficacy of safety of venlafaxine XR and paroxetine in the short-term treatment of SAD by D. Hackett; M. Liebowitz; R. Mangano (S381).
P.3.065 Patient-reported functioning in SAD and improvement with treatment: A comparison of venlafaxine XR, paroxetine, and placebo by D. Baldwin; N. DeMartinis; R. Mallick (S381-S382).
P.3.066 PTSD - early intervention with sertraline: Preliminary data from prospective study by J. Zohar; O. Karamustafolioglu (S382).
P.3.067 Decreased lymphocyte 3H-paroxetine binding in obsessive-compulsive disorder by I. Masala; S. Baroni; L. Betti; G. Giannaccini; F. Mungai; D. Marazziti (S382-S383).
P.3.050 Pooled analysis of symptom-free days in generalized anxiety disorder by G. Wan; H.F. Zhang (S374-S375).
P.3.049 Decreased temporal lobe volume in panic disorder - a quantitative morphometric MRI study by T. Sobanski; G. Wagner; U. Gruhn; K. Schluttig; R. Tauber; G. Peikert; H. Sauer (S374).
P.3.033 Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines by M. Tabiner; S. Youings; N. Dennis; D. Baldwin; C. Buis; A.G. Mayers; P.A. Jacobs; J.A. Crolla (S367).
P.3.032 Effects of DHEA-S on sexual motivation in anxious male mice with opposite social statuses by A. Amikishieva; M. Ovsyukova (S367).
P.3.034 Joint hypermobility syndrome in panic disorder patients with and without mitral valve prolapse by D. Gulpek; E. Bayraktar; S. Pyryldar; K. Capacy; M. Kayykcyoglu; E. Aliyev; C. Soydas (S367-S368).
P.3.035 Generalized anxiety and major depression in a Belgian primary care setting, influence by socio-economic factors. The GADIS II study by A. Mignon; B. Fischler; M. Ansseau; M. Dierick; S. Leyman (S368).
P.3.036 Psychosocial sequelae of the 1998 Ceyhan-Adana earthquake. A prospective study by S. Uguz; G. Seydioglu (S368-S369).
P.3.031 A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of PTSD by E. Önder; Ü. Tural; T. Aker (S366-S367).
P.3.030 A polymorphism study of serotonin transporter gene (5-HTTLPR) in Korean social phobia patients by K.S. Oh; H.K. Yoon; M.S. Lee; Y.C. Shin (S366).
P.3.026 Fixed doses of escitalopram and paroxetine for the treatment of social anxiety disorder (SAD) by M. Lader; K. Stender; V. Bürger; R. Nil (S364).
P.3.027 Activity in the fear-potentiated startle (FPS) in rodents and healthy subjects with LY354740, a novel mGlu2/3 receptor agonist by L. Levine; R.P. Landbloom; D.D. Schoepp; J.P. Tizzano; C. Grillon (S364-S365).
P.3.028 Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers by J. Boyle; L. Trick; S. Soo-ampon; S. Lilley; L. Levine; I. Hindmarch (S365).
P.3.029 Efficacy of sertraline in improving quality of life and functioning in generalized anxiety disorder (GAD) by I. Sjodin; S.P. Kutcher; A. Ravindran; T. Butt (S365-S366).
P.3.037 Treatment decision-making in panic disorder with agoraphobia by V. Starcevic; E.H. Uhlenhuth (S369).
P.3.038 Escitalopram versus placebo in Social Anxiety Disorder (SAD): Better effectiveness, lower costs and improved quality of life by S.A. Montgomery; C. François; N. Despiegel (S369-S370).
P.3.045 Role of gonadal steroids in the anxiolytic action of benzodiacepines in male and female mice lacking cannabinoid CB1 receptors by L. Urigüen; M. Grau; S. Pérez-Rial; S. Ortiz; J.M. Oliva; T. Palomo; J. Manzanares (S372).
P.3.046 Altered emotional states and impaired anxiolytic action of benzodiacepines in mice lacking cannabinoid CB1 receptors by L. Urigüen; S. Pérez-Rial; S. Ortiz; J.M. Oliva; T. Palomo; J. Manzanares (S373).
P.3.047 Autoantibody binding profile to the brain and pituitary in neuropsychiatric disorders by S. Fetissov; J. Hallman; L. Oreland; T. Hökfelt (S373).
P.3.048 Generalized anxiety disorder (GAD): Gender differences in clinical presentation and response to sertraline by M. Steiner; C. Allgulander; A. Ravindran; T. Burt (S374).
P.3.044 Social anxiety disorder and female reproductive hormones: Is there a connection? by J.F. Van Veen; B.W. Jonker; I.M. Van Vliet; F.G. Zitman (S372).
P.3.043 Dopamine transporter density changes of basal ganglia with SSRI treatment i patients by M.-S. Koo; C.H. Kim; K.-A. Cheon; H.S. Suh; H.S. Lee; Y.-H. Ryu (S371).
P.3.039 The implication of 5-HT2 receptor subtypes in the anxiolytic-like efforts of peroxetine in the mouse four plate test by B.A. Nic Dhonuchandha; N. Ripoll; M. Hascoët; P. Jolliet; M. Boerin (S370).
P.3.040 Relapse in social anxiety disorder (SAD): Costs and quality of life by D. Servant; S.A. Montgomery; C. François (S370).
P.3.041 Effects of SKF 10047, a sigma selective agonist, on anxiety tested in the elevated plus maze in male mice by D. Beltrán; M. Cavas; J.F. Navarro (S370-S371).
P.3.042 TNF-alpha accounts for stress-induced short-term persistency of oxidative status in rat brain by C. Munhoz; J.L.M. Madrigal; B. García-Bueno; M.P. Pereira; M.A. Moro; I. Lizasoain; P. Lorenzo; J.C. Leza (S371).
P.2.142 Male sexual dysfunction, adherence to antipsychotic therapy and the quality of life in schizophrenia. Comparison of olanzapine and risperidone by B. Konarzewska; I. Rudnik; A. Szulc; D. Juchnowicz; R. Poplawska (S341).
P.2.141 Antipsychotic efficacy of olanzapine in pretreated schizophrenic patients: Findings from a naturalistic drug utilization observation phase IV study by M. Kluge; J. Czekalla; P.M. Wehmeier; T. Wagner; M. Linden; R.W. Dittmann (S341).
P.2.075 A naturalistic retrospective health outcome study comparing typical or atypical antipsychotic drug treatments during 10 years by E. Lindström; P. Svanberg; M. Markus (S312).
P.2.074 Psychotropic polypharmacy among medicaid subjects by M. Rupnow; J.S. Markowitz; A. Grogg (S311-S312).
P.2.076 Strategies for assuring continuity of antipsychotic treatment at the interface between inpatient and outpatient treatment of patients with schizophrenia by J. Hamann; B. Langer; W. Kissling (S312-S313).
P.2.077 Neurological soft signs in first-episode schizophrenia by E. Ceskova; R. Prikryl; T. Kasparek; E. Tronerova (S313).
P.2.078 Quetiapine improves symptoms and is well tolerated in patients with schizophrenia switched from olanzapine by I. Larmo (S313-S314).
P.2.073 No seizure exacerbation from ziprasidone in youth with comorbid epilepsy and psychiatric disorders: A case series by J. Gonzalez-Heydrich (S311).
P.2.072 A French cohort study on olanzapine prescription over a 12 months period by V. Olivier; A. Fourrier; I. Gasquet; P. Flandre; E. Perrin (S310-S311).
P.2.068 Antipsychotic treatment for schizophrenia: Effects on sexual function by C. Osvaldo; M. Dossenbach; J.M. Tamayo; D. Soria; C. Na; S. Singh; K.-H. Wu (S308-S309).
P.2.069 Quality of life and clinical outcomes for Asian outpatients with schizophrenia: A double-blind randomised comparison of olanzapine and haloperidol by H.R. Chaudhry; R. Kongsakon; J.C. Ignacio; S.B. Raza; M.C.R. Leynes; C.I. Hasanah; B. Chan; P. Onate; A.J.M. Brnabic; A.J. Lowry; R. Buenaventura (S309).
P.2.070 Treatment of resistant auditory hallucinations with quetiapine: Two case reports with cognitive assessment by S.N. Mosolov; S. Kabanov (S309-S310).
P.2.071 Regional cerebral blood flow changes associated with quetiapine treatment in schizophrenic patients without extrapyramidal symptoms by A.S. Gonul; M. Kula; A. Oguz; A. Tutus; H.B. Izgi (S310).
P.2.079 Open-label study of risperidone in children with bipolar disorder by J. Biederman (S314).
P.2.080 Risperidone in the treatment of acute bipolar mania: A double-blind, placebo-controlled study of 290 patients by S. Khanna; E. Vieta; B. Lyons; F. Grossman; M. Kramer (S314-S315).
P.2.087 Risperidone monotherapy in acute bipolar mania by M. Kramer; K. Karcher; F. Grossman (S317-S318).
P.2.088 Dopaminergic system genes and performance on prefrontal test in schizophrenia by J. Rybakowski; A. Borkowska; P.M. Czerski; J. Hauser (S318).
P.2.089 Switching from clozapine to zotepine in schizophrenic patients: A randomized, single-blind controlled study by C.-C. Lin; Y.-M. Bai; J.-Y. Chen; Y.-C. Wang; Y.-J. Liou; C.-H. Chao; I.-C. Lai; K.-Y. Tsai; H.-J. Chiu (S318-S319).
P.2.090 Metabolite abnormalities in glutamatergic system measured by proton magnetic resonance spectroscopy (1H MRS) in schizophrenic patients by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; W. Dzienis; A. Czernikiewicz; J. Walecki (S319).
P.2.086 Atypical antipsychotics and time of hospitalization by M. García Mahía; M. Vidal Millares; R. Garcia Ramos; C. Pedrejon Molino; C. Borras (S317).
P.2.085 Amphetamine and stress-induced behaviors and c-Fos expression in a genetic model of NMDA receptor hypofunction by S. Miyamoto; J.N. Snouwaert; B.H. Koller; J.A. Lieberman; G.E. Duncan (S317).
P.2.081 A preliminary study of the pharmacokinetics and tolerability of higher dose oral olanzapine (20, 30, or 40mg/day) in stable patients with serious mental disorders by M. Mitchell; W. Earley; M.A. Bari; R.A. Riesenberg; E. Marquez; D. Kurtz; D. Falk; C.C. Taylor; P. Cavazzoni (S315).
P.2.082 Cognitive function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine by W. Deberdt; P.P. De Deyn; M.M. Carrasco; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier (S315).
P.2.083 Pilot study of the effects of rivastigmine in schizophrenia by K.M. Van de Graaff; A.J.M. Loonen; J.E.J.M. Hovens; A. Van Dijke; J.H.M. Tulen (S315-S316).
P.2.084 A comparison of olanzapine and risperidone for the schizophrenic patients intolerance of neuroleptic-induced extrapyramidal syndromes (EPS) by H.Y. Chan; C.H. Chen; J.J. Chen; H.J. Sun; H.-J. Chiu; C.J. Chang (S316-S317).
P.2.067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophrenia by S. Kasper; A.J. Lowry; A. Hodge; I. Bitter; M. Dossenbach (S308).
P.2.066 Effectiveness of antipsychotic treatments for patients from the Central Eastern Europe (CEE) region participating in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study: 6-month results by J. Pečeňák; P. Kaps; T. Treuer; I. Bitter; A. Hodge; A. Grigoriu; I. Trzebiatowska; E. Herman; D. Peciukaitiene; S. Smulevich; M. Kökényes (S307-S308).
P.2.050 Varying degree of risks of developing new onset diabetes mellitus in patients treated with atypical antipsychotics by F.G. Pajonk (S300-S301).
P.2.049 Investigation of the metabolic effects of antipsychotics in patients with schizophrenia by P. Chue; R. Welch (S300).
P.2.051 Ziprasidone negative symptom efficacy in long-term clinical trials by N.R. Schooler; S. Murray; C.O. Siu; S.J. Romano (S301).
P.2.052 Addition of nicotine to the D2 antagonist raclopride or the weak D4 antagonist L-745,870 augments NMDA-induced currents in pyramidal cells from the rat medial prefrontal cortex by M.M. Marcus; K.E. Jardemark; Å. Konradsson; T.H. Svensson (S301).
P.2.053 Effect of acute and chronic treatment with the atypical antipsychotics olanzapine and clozapine in 8-radial arm maze in rats by A. Ortega-Alvaro; J. Gibert-Rahola; J.A. Micó (S301-S302).
P.2.048 Efficacy of intramuscular ziprasidone without adjunctive benzodiazepines by D.G. Daniel; S. Brook; I. Benattia (S299-S300).
P.2.047 Analysis of motor function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine by W. Deberdt; M.M. Carrasco; C. Jeandel; D.P. Hay; P.D. Feldman; C.A. Young; D.L. Lehman; A. Breier; P.P. De Deyn (S299).
P.2.043 Treatment of acutely exacerbated including highly agitated schizophrenic patients with oral risperidone by A. Schreiner; F.G. Pajonk; S. Peters; E. Ruether (S297).
P.2.044 The specificity of autobiographical memory and emotional disturbance in schizophrenia by D. Lecompte; A. Neumann; S. Blairy; P. Philippot; J.M. Danion (S298).
P.2.045 A family overloaded with psychosis and rickets-alopecia syndrome challenges vitamin-D hypothesis for schizophrenia by S. Ozer; A. Ulusahin; S. Ulusoy; H. Okur; T. Coskun; A. Gogus; A.N. Akarsu (S298-S299).
P.2.046 Ziprasidone versus risperidone in schizophrenia: 52 weeks' comparative data by D. Addington; C. Pantelis; M. Dineen; I. Benattia; S.J. Romano; S. Murray (S299).
P.2.054 Adherence to antipsychotic dosing guidelines in the treatment of hospitalised psychotic patients in Belgium by J. Peuskens; M. Wampers; I. Fernandez; E. Thys; S. Wyckaert; M. De Hert (S302).
P.2.055 The influence of antipsychotic drug treatment on anticholinergic use and complexity of medication schemes in hospitalised pschotic patient in Belgium by M. De Hert; M. Wampers; I. Fernandez; E. Thys; S. Wyckaert; J. Peuskens (S302-S303).
P.2.062 Risperidone but not haloperidol regulates hippocampal neuroplasticity in rats by S. Mahadik (S306).
P.2.063 Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics by L. Citrome; A. Jaffe; J. Levine; B. Allingham; J. Robinson (S306).
P.2.064 Managing schizophrenia in patients with co-morbid diabetes: A case report and literature review by M. Green (S306-S307).
P.2.065 The relationship between the therapeutic response to antipsychotic drugs and dopamine D2 receptor polymorphism in Korean schizophrenic patients by C.J. Kang; J.-M. Park; S.-G. Kim; C.M. Kim (S307).
P.2.061 Long-acting risperidone injection improves and maintains quality of life in patients with schizophrenia by A. Mehnert; M. Eerdekens; W.W. Fleischhacker (S305).
P.2.060 Antidepressant-type effects of olanzapine in modified FST in rats by B.L. Cobo-Realpe; M.O. Rojas-Corrales; E. Berrocoso; J. Gibert-Rahola; J.A. Micó (S305).
P.2.056 Sound and vision, using popular media to improve knowledge about schizophrenia by E. Thys; M. De Hert; G. Magiels; S. Wyckaert; J. Peuskens (S303).
P.2.057 Clinical improvement with long-acting risperidone in patients previously receiving oral olanzapine by R. Jones; R. Lasser; C. Bossie (S303-S304).
P.2.058 Pharmacodynamic differences between ziprasidone, risperidone and haloperidol: A 123I-IBZM study by M. Ferrer Vinardell; I. Corripio Collado; G. Safont Lacal; R. Pérez Egea; V. Pérez Solá; E. Alvarez Martínez (S304).
P.2.059 Comparative efficacy of risperidone, clozapine and haloperidol in the treatment of schizoaffective disorders with manic symptoms by N. Malykhin (S304).
P.2.091 Residential care in Italy. Preliminary clinical and psychosocial data of community living versus non-hospital residential facilities treated chronic schizophrenics by S. Zizolfi; W. Bargna; G. Cilli; R. Pirisi (S319-S320).
P.2.092 Quality of life and cognitive functions in schizophrenia by Y. Akvardai; B.B. Kivircik; K. Alptekin; K. Dumlu; D. Isik; F. Pirincci; S. Yahssin; A. Kitis (S320).
P.2.125 A six-month, double-blind, controlled trial in schizophrenic patients comparing amisulpride and olanzapine by A. Mortimer; W. Rein; O. Fleurot (S334).
P.2.124 Treatment of cognitive impairment in recent onset psychosis; a comparison of risperidone and haloperidol by M. Davidson; N. Schooler; J. Rabinowitz (S334).
P.2.126 Evidence for aspartate as a neurotransmitter in the mediodorsal thalamus-medial prefrontal cortex pathway by J. Glennon; W.T. O'Connor (S334-S335).
P.2.127 Aripiprazole in pediatric-conduct disorder: A pilot study by R.L. Findling; J.L. Blumer; R. Kauffman; J.R. Batterson; D.L. Gilbert; S. Bramer; R. Marcus (S335).
P.2.128 Metabolic effects associated with antipsychotic therapy in a naturalistic setting by D. Schreinzer; M. Letmaier; C. Barnas; S. Kasper (S335-S336).
P.2.123 Atypical antipsychotic treatment-related urinary incontinence: A urodynamic evaluation by G. Martino; S. Isgrò; G. Martino; E. Di Rosa; R. Zoccali; G. Citto; M. Meduri (S333-S334).
P.2.122 Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole by S. Bramer; S. Shoaf; D. Salazar; S. Mallikaarjun (S333).
P.2.118 SPECT quantification of in vivo dopamine D2 receptor occupancy with risperidone microspheres by G. Wiesegger; N. Klein; S. Asenbaum; T. Attarbaschi; N. Mossaheb; R. Dudczak; S. Kasper; J. Tauscher (S331-S332).
P.2.119 Predictors of non-adherence with antipsychotic medication and health service use — an analysis of the United Kingdom psychiatric morbidity survey by K. Pugner; M. Knapp; D. King; P. Lapuerta (S332).
P.2.120 Time of dosing and food effect on aripiprazole pharmacokinetics by S. Mallikaarjun; Y. Riesgo; D. Salazar; S. Bramer; J. Xie; I. Weston (S332-S333).
P.2.121 Aripiprazole vs. haloperidol for maintained treatment effect in acute mania by M. Bourin; P. Auby; S. Swanik; R. Marcus; R. McQuade; T. Iwamoto; R. Sanchez (S333).
P.2.129 Risk for akathisia in patients with recent onset schizophrenia treated with risperidone and haloperidol and its association with suicidality by R.A. Emsley; M. Davidson; J. Rabinowitz (S336).
P.2.130 Evidence for a mediodorsal thalamic NMDA receptor regulation of local and medial prefrontal cortex aspartate release by J. Glennon; W.T. O'Connor (S336).
P.2.137 Attitudes regarding sexual functioning among early episode schizophrenia patients by J. Rabinowitz; M. Davidson (S339).
P.2.138 Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychotics by T. Hardy; M.O. Sowell; E. Marquez; P. Cavazzoni; C.C. Taylor; A. Breier (S339-S340).
P.2.139 Effectiveness of quetiapine up to 1600 mg/day: Short-term results with 14-month follow-up by J. Nagy (S340).
P.2.140 A comparison of the efficacy and safety of quetiapine and risperidone by X. Zhong; D. Sweitzer; J. Russo; L. Potter; J. Mullen (S340).
P.2.136 Premorbid functioning and outcomes in recent onset schizophrenia by J. Rabinowitz; G. De Smedt; M. Davidson (S338-S339).
P.2.135 Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: A comparison of risperidone and haloperidol by L. Kopala; J. Rabinowitz; M. Davidson (S338).
P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia by R.S. Kahn; J.A. Lieberman; C. Charles; T. Sharma; R.B. Zipursky; R. Gur; M. Tohen; A.I. Green; J.P. McEvoy; D.O. Perkins; R.M. Hamer; C.B. Nemeroff; A.J. Rothschild; J. Kuldau; S.M. Strakowski; G.D. Tollefson (S337).
P.2.132 Reduced relapse rates in recent onset schizophrenia patients treated with risperidone vs. haloperidol by N. Schooler; M. Davidson; L. Kopala (S337).
P.2.133 Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1) by M. Brecher; K. Huizar (S338).
P.2.134 Pharmacokinetics of ziprasidone in pediatric versus adult subjects by J.J. Miceli; S. Murray (S338).
P.2.117 Development of a genetic test for the prediction of clozapine response by H.M. Puehringer; M.J. Arranz; R.W. Kerwin; F. Kury; C. Oberkanins (S331).
P.2.116 Guanosine-5′-O-(3-[35S]THIO)-triphosphate binding assays can be insensitive in detecting D2 partial agonist drug activity by S. Jordan; R. Chen; J. Johnson; K. Regardie; R. Whitehead; Y. Tadori; R. McQuade; T. Kikuchi (S331).
P.2.100 Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: A comparative study by S. Lis; S. Krieger; B. Gallhofer; P. Torre; A. Mittoux; F. Menard (S323-S324).
P.2.099 A prevalence study of impaired glucose tolerance and diabetes mellitus in hospitalized patients with schizophrenia by D. Taylor; C. Young; R. Mahomed; C. Paton (S323).
P.2.101 The dosing pattern and clinical outcome of psychosis: A cluster analysis on 2078 cases with risperidone treatment by C.Y. Kim; S.-K. Choi; G.H. Lee; Y.-W. Shin; C. Lee (S324).
P.2.102 Aripiprazole treatment for psychosis in patients with Alzheimer's disease by P.P. De Deyn; D. Jeste; P. Aubrey; H. Goyvaerts; C. Breder; L. Schneider; J. Mintzer (S325).
P.2.103 Topiramate in the treatment of overweight and obesity in schizophrenia: A pilot study in Korea by Y.-H. Ko; B.-G. Kim; W. Cho; K.-H. Lee; J.-H. Park (S325).
P.2.098 Risperidone augmentation on resistant depression by A. Young; F. Rouillon; C. Canuso; C. Bossie; G. Gharabawi (S323).
P.2.097 The immune system abnormalities in first-episode schizophrenia by A. Szulc; B. Galinska; B. Konarzewska; R. Poplawska; A. Czernikiewicz (S322-S323).
P.2.093 Marked increase in adiposity during olanzapine vs risperidone treatment: Results of a placebo-controlled study in normal dogs by M. Ader; S.P. Kim; K.J. Catalano; V. Ionut; K. Hucking; J.M. Richey; M. Kabir; R.N. Bergman (S320-S321).
P.2.094 Prediction of the risk of antipsychotic-associated coronary heart disease by K. Trakas (S321).
P.2.095 Atypical antipsychotics, weight gain, hyperglycemia, and lipid abnormalities: A two-year naturalistic study by Ö. Uzun; A. Cansever; H. Aydyn; B. Özdemir; C. Çelik (S321-S322).
P.2.096 No association between serotonin transporter polymorphism and schizophrenia by P. Kapelski; P. Czerski; J. Hauser; A. Leszczynska-Rodziewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Rybakowski (S322).
P.2.104 Hunting the susceptibility gene for psychosis: A study of a family overloaded with different forms of psychotic disorders by S. Ozer; S. Ulusoy; H. Okur; A. Gogus; A.N. Akarsu; A. Ulusahin (S325-S326).
P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia by R. McQuade; D. Jody; J. Kane; W. Carson; M. Kujawa; J. Stringfellow; R. Marcus; R. Sanchez; H.Y. Meltzer (S326).
P.2.112 Clozapine decreases tyrosine hydroxylase level in PC12 cells by a Gi/Go protein dependent presynaptic mechanisms by P. Tejedor-Real; N. Faucon Biguet; J. Mallet (S328-S329).
P.2.113 An open-label trial of topiramate adjunct in bipolar patients with mood instability by C. Binder; R. McIntyre; R. Riccardelli; V. Kusumakar (S329).
P.2.114 Cross-domain analyses in schizophrenia — results from human brain informatics studies by H. Hall; S. Arnborg; I. Agartz; A. Sillén; E.G. Jonsson; B. Edman; H. Nyman; L. Terenius; G. Sedvall (S330).
P.2.115 PET examinations or thalamic D2 receptors in schizophrenic patients by M. Talvik; A.L. Nordström; H. Olsson; C. Halldin; L. Farde (S330).
P.2.111 Long-term effects of aripirazole on the negative symptoms of schizophrenia by D. Kostic; G. Manos; E. Stock; D. Jody; D. Archibald; S. Tourkodimitris; R. Marcus (S328).
P.2.110 A case of schizophrenia-like psychosis in a patient with temporal arachnoid cyst by M. Fontana; T. Di Fonzo; C. Aliquò; A. Hadjichristos (S328).
P.2.106 Change in clinical status and quality of life of schizophrenic patients in Germany: Six month results from the schizophrenia outpatient health outcomes (SOHO) study by D. Naber; M. Krausz; R.W. Dittmann; C. Mahl; F. Langer; T. Wagner; P. Linder; D. Novick; J. Czekalla (S326-S327).
P.2.107 Brain activation patterns during prepulse inhibition (PPI) in first episode schizophrenia and health controls using H2 15O-PET by F.X. Vollenweider; M. Benz; M. Etzensberger; K. Ludewig; D. Hell (S327).
P.2.108 Plasma lipids levels and glycemic control in long-term treatment with aripiprazole by E. Stock; S.R. Marder; D. Jody; S. Kaplita; A. Saha; W. Carson; A. Torbeyns (S327).
P.2.109 A double-blind placebo-controlled trial of risperidone in autistic disorder by C.J. McDougle; M.G. Aman; J.T. McCracken; L. Scahill; E. Tierney; B. Vitiello (S327-S328).
P.3.074 In vivo pharmacological profile of SB-616234-A, a selective 5-HT1B receptor antagonist, in animal models of anxiety and antidepressant-like behaviour by R. Arban; A. Poffe; L. Bettelini; F. Bacchi; P.A. Gerrard; S. Melotto (S386).
P.3.075 Duration of untreated illness in panic disorder: A poor outcome risk factor? by E. Mundo; A. Santini; D. Salvadori; A.C. Altamura (S386).
P.6.029 Fractal analysis of magnetic resonance images in schizophrenia and obsessive-compulsive disorder by J.S. Kwon; U. Yoon; J.M. Lee; T.H. Ha; L.Y. Kim; S.I. Kim (S438).
P.6.028 Mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age by S.P. Roose; P. Holland; H. Hassman; M. Rosenthal; J.H. Simmons; H. Rodrigues (S437).
P.6.030 Brain-derived neurotrophic factor polymorphism in patients with schizophrenia by A. Juhasz; A. Rimanoczy; S.Z. Keri; G.Y. Szekeres; Z. Janka (S438).
P.6.031 An association of the serotonin receptor (5HT2A) gene and serotonin transporter (5HTTLPR) gene in anorexia nervosa by M. Dmitrzak-Weglarz; F. Rybakowski; A. Slopien; P. Czerski; J. Hauser; A. Rajewski (S438-S439).
P.6.032 Complex partial scizure-like symptoms, dissociation and traumatic stress in depressed patients by P. Bob; R. Ptacek; I. Paclt; P. Zvolsky; D. Jasova; J. Pavlat; M. Pav (S439).
P.6.027 Effects of secluded areas in a psychiatric acute ward by A.E. Vaaler; G. Morken; J.C. Flovig; V.C. Iversen; O.M. Linaker (S437).
P.6.026 Caffeine influenced time-perception in humans by I. Ghita Cristescu; O. Comar; O. Savo; C. Rotar; I. Fulga (S436-S437).
P.6.022 5-HT2A receptor but not 5-HT transporter gene polymorphism is associated with harm avoidance in adolescents with anorexia nervosa by F. Rybakowski; M. Dmitrzak-Weglarz; A. Slopien; J. Hauser; A. Rajewski (S435).
P.6.023 Association study of dopamine system genes in anorexia nervosa by A. Slopien; F. Rybakowski; M. Dmitrzak-Weglarz; J. Hauser; A. Rajewski (S435-S436).
P.6.024 Temperament and character inventory and treatment outcome in pharmacotherapy of bulimia nervosa by F. Rybakowski; A. Rajewski (S436).
P.6.025 Neuropsychological correlations of obsessive-compulsive disorder symptom dimensions by T.H. Ha; J.S. Kwon; K.S. Roh; H.S. Park; M.S. Kim (S436).
P.6.033 Decline in CYP2D6 metabolising capacity in the elderly by K. Tandon; M. Kinirons; M. Patel; P. McGuffin; K.J. Aitchison (S439-S440).
P.6.034 Endocrine responses to ghrelin in patients with eating disorders by G. Abbate Daga; V. Mondelli; P. Leombruni; S. Destefanis; F. Broglio; F. Facchini; S. Defilippi; R. Rosetto; F. Lanfranco; R. Deghenghi; E. Ghigo; L. Gianotti; S. Fassino (S440).
P.6.041 Mental disorders in patients with Lyme disease by I. Rudnik; R. Poplawska; A. Szulc; D. Juchnowicz; B. Konarzewska; A. Czernikiewicz; I. Debowska (S443).
P.6.042 Species differences in the antinociceptive activity of 3-carbomethoxy fentanyl (iso-carfentanil) by M. Prostran; S. Vuckovic; M. Ivanovic; Z. Todorovic; Z. Nesic; R. Stojanovic (S444).
P.6.043 No association between DRD4 gene -521 C/T polymorphism with schizophrenia and bipolar affective disorder by P. Czerski; M. Dmitrzak-Weglarz; P. Kapelski; A. Leszczynska-Rodziewicz; M. Kosmowska; M. Perucki; J. Hauser (S444).
P.6.044 Repetition of suicidal behaviour following deliberate self-poisoning with pesticides by K. Naudts; G. Portzky; K. Audenaert; C. Van Heeringen (S444-S445).
P.6.040 Is the Brugada electrocardiogram associated with antipsychotic and antidepressant treatment? by S. Kounas; O. Rouvali; P. Dalli; M. Efremidis; S. Theodoropoulou; F. Kardaras (S443).
P.6.039 Correlation of brain perfusion and cognitive functions in sleep apnea patients: A study with Tc-99m HMPAO in sleep laboratory by P. Kiratli; B. Volkan; A. Demir; B. Demir; A. Sahin (S442-S443).
P.6.035 Diffusion-weighted MRI study of corpus callosum in patients with schizophrenia. Preliminary findings by P. Brambilla; R. Cerini; C. Barbui; A. Gasparini; M. Nose; A. Versace; E. Vittom; N. Andreone; M. Gregis; A. David; M.S. Keshavan; C. Procacci; M. Tansella (S440-S441).
P.6.036 Comparison of divalproex and gabapentin: Effectiveness in aggressive youth by S. Komdorfer; W. Beardslee; J. Gonzalez-Heydrich (S441).
P.6.037 Effect of 5-HT2C receptor activation on reward and loss response patterns in humans detected by fMRI by J. Stirling; B. Völlm; P. Richardson; C. Del Ben; R. Elliott; I. Anderson; S. McKie; B. Deakin; W. Williams (S441-S442).
P.6.038 Acute exposure to higher ambient temperature potentiates cataleptic and hyperthermic effects of fentanyl in female rats by M. Prostran; Z. Nesic; S. Vuckovic; M. Prostran; Z. Todorovic; R. Stojanovic; M. Ivanovic (S442).
P.6.021 Anxiety, depression and disease specific quality of life in dermatologic patients by A. Yazici; K. Baz; K. Yazici; A. Köktürk; Y. Okyay; A. Cordan Yazici; D. Demirseren (S435).
P.6.020 Association of the TAP2 gene with schizophrenia in the Korean population by T.Y. Jun; K.-U. Lee; J.M. Song; C.U. Pae; J.H. Chae; W.M. Bahk; K.S. Kim (S434-S435).
P.6.004 Study of substance use impact on the severity of parasuicide by M. Tournier; M. Molimard; A. Abouelfath; A. Cougnard; A. Fourier; H. Verdoux (S428).
P.6.003 Reduced hypothalamic-pituitary adrenal axis activity in children with attention deficit hyperactivity disorder and matched controls by D. Van West; S. Claes; J. Sulon; D. Deboutte (S428).
P.6.005 Olanzapine treatment in children with oppositional defiant disorder (ODD) and aggressive, antisocial behavior by D.H. Shawn; I. Shawn (S429).
P.6.006 Effects of early parental seperation due to divorce on young adults — assessment of the hypothalamic-pituitary-adrenal axis using the corticotropin releasing hormone stimulation test by M. Bloch; I. Peleg; D. Koren; E. Klein (S429).
P.6.007 Acute and subchronic effects of gammahydroxybutyrate (GHB) on isolation induced aggression in male mice by J.F. Navarro; F. González; C. Pedraza (S429-S430).
P.6.002 Behavioral phenotyping of GSK-3 beta knockout heterozygote mice by Y. Bersudsky; A. Shaldubina; G. Agam; N. Kozlovsky; K. Hoeflich; J.R. Woodgett; R.H. Belmaker (S428).
P.6.001 Relationships between DRD2 and DAT polymorphisms and personality traits in healthy subjects by E. Pinto; J. Reggers; M. Hansenne; W. Pitchot; S. Fuchs; P. Gorwood; D. Vaira; M. Ansseau (S427-S428).
P.5.047 Evidence for the role of nitric oxide in caffeine-induced locomotor activity in mice by H. Kayir; I.T. Uzbay (S426).
P.5.048 Effects of fluoxetine on ethanol withdrawal syndrome in rats by H. Kayir; E. Saglam; T. Çelik; M. Beyazyurek; I.T. Uzbay (S426-S427).
P.5.049 Behavioral effects of ethanol at low doses: The involvement of dopamine D2 receptors by M. Castorina; F. Drago (S427).
P.6.000 Brain-derived neurotrophic factor in amygdala-dependent fear conditioned learning by K. Ressler; L.S. Rattiner; M. Davis (S427).
P.6.008 An ethopharmacological assessment of the effects of SKF 10047, a sigma-1 selective agonist, on social interactions between male mice by D. Beltrán; M. Cavas; J.F. Navarro (S430).
P.6.009 Possible psychosocial factors for sexual dysfunctions of Turkish males: A descriptive study by S. Uguz; M.L. Soylu (S430-S431).
P.6.016 Type A behavior and estrogen levels in women under 50 years old with acute coronary syndrome by J. Dragicevic; Z. Vasiljevic; M. Drezgic; V. Bisenic; P. Mitrovic; M. Krotin (S433).
P.6.017 Systematic screen of serotonergic genes on suicidal behaviour by I. Giegling; D. Rujescu; R.R. Engel; H.-J. Möller (S433).
P.6.018 Altered glucocorticoid receptor functioning in aging: Implications for hypothalamic-pituitary-adrenocortical (HPA) system dysfunction by M. Hatzinger; S. Brand; N. Herzig; E. Holsboer-Trachsler (S434).
P.6.019 Oxcarbazepine in the management of behavioral agitation in community-dwelling patients with Alzheimer's disease: An open-label study by J. Shua-Haim (S434).
P.6.015 Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder by M.Y. Chung; Y.J. Jun; S.S. Kim; W.C. Kim; K.H. Min (S433).
P.6.014 The frequency and associated factors of excessive daytime sleepiness in Korean young men by S.P. Lee; S.C. Hong; J.H. Han; J.H. Jeong; S.H. Lim (S432-S433).
P.6.01 Evaluation of risperidone mutagenic action by sister chromatide exchange test by A. Damjanovic; M. Ivkovic; M. Jasovic-Gasic; V.R. Pauncvic (S431).
P.6.011 Subtypes of autism by cluster analysis based on structural MRI data by M. Hrdlicka; I. Dudova; I. Beranova; J. Lisy; T. Belsan; J. Neuwirth; V. Komarek; L. Faladova; Z. Sedlacek; M. Havlovicová; M. Blatny; T. Urbanek (S431-S432).
P.6.012 Carbamazepine for the treatment of behavioral disturbances of dementia by R. Krsteska; V. Filovska; M. Jakovcevska-Kujundziska (S432).
P.6.013 Step forward in research of chronic ischemic brain disease during Semax therapy by K. Cherkasova (S432).
P.6.045 SSRI fail to improve AN treatment in first weeks of treatment by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Krzystanek; J. Szymszal (S445).
P.6.046 Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration by S.H. Kim; B.H. Yang; H. Son; J.H. Nam; J.H. Choi; J.S. Lee; H.S. Oh; K.S. Rho; D.H. Oh (S445).
P.6.080 Long-term exposure to lithium therapy and side effects with common dosing by V. Filovska; M. Jakovcevska-Kujundziska; M. Lazarova; R. Krsteska (S459-S460).
P.6.079 [3H]-Ketanserin binding sites in different psychiatric disorders by D. Marazziti; G. Giannaccini; A. Giromella; L. Betti; S. Baroni; I. Masala; A. Lucacchini; G.B. Cassano (S459).
P.6.081 Topiramate in bipolar and schizoaffective disorders by A. Theodorou; C. Kalkavoura; P. Theodoropoulou; A. Georgiou; E. Tzebelikos (S460).
P.6.082 An open case study in Italy of oxcarbazepine, an effective mood stabiliser, in patients with drug resistant/intolerant bipolar I disorder by F. Frare; G. Perugi; C. Toni; G. Ruffolo; H.S. Akiskal (S460-S461).
P.6.083 Management of attention-deficit/hyperactivity disorder (ADHD) in The Netherlands by N. Vanoverbeke; L. Annemans; M. Ingham; I. Adriaenssen (S461).
P.6.078 DRD4 gene polymorphism in Turkish children and adolescents with developmental stuttering by A. Ertekin Yazici; F. Toros; E. Erdal; S. Zoroglu; S. Tot; A. Yazici Ertekin (S459).
P.6.077 Long-term effects of atomoxetine on growth in children with APHD by D. Michelson; T. Spencer; D. Ruff; P.D. Feldman (S458-S459).
P.6.073 Treatment and economic outcomes in patients with bipolar disorder by K. Davis; N. Calvert; A. Lloyd; M. O'Leary; P. Youman (S457).
P.6.074 Effects of lamotrigine on quality of life in patients with bipolar I disorder by M. Rapaport; S. Kennedy; K. Davis (S457-S458).
P.6.075 Effects of atomoxetine treatment on executive functioning in adults with attention-deficit/hyperactivity disorder (ADHD) by J. Biederman; S. Faraone; T. Spencer; D. Michelson; D. Jones; L. Adler (S458).
P.6.076 Long-term treatment effects of atomoxetine in adults with attention-deficit/hyperactivity disorder (ADHD) by D. Michelson; L. Adler; T. Spencer; D. Milton; D. Jones (S458).
P.6.084 Apolipoprotein E genotype in Korean schizophrenic patients by B.W. Nam; J.S. Seo (S461-S462).
P.6.085 Synergistic effects of quetiapine in combination with fluvoxamine on dopamine release in rat prefrontal cortex by H.G.M. Westenberg; D. Denys; A.A. Klompmakers (S462).
P.6.092 Both methylphenidate and acetyl-L-carnitine reduce impulsivity in adolescent SHRs, an animal model of ADHD by W. Adriani; M. Baviera; W. Invernizzi; M. Carli; A. Caprioli; O. Ghirardi; G. Laviola (S465).
P.6.093 Effects of zalepon and zolpidem on driving ability: Evidence from on-the-road driving studies during normal traffic by E.R. Volkerts; J.C. Verster (S465).
Author index (S467-S482).
Keyword index (S483-S488).
P.6.091 Follow-up study of the effects of carbamazepine in the treatment of impulsiveness in patients with personality disorders by M. Todorovic; I. Timotijevic (S464-S465).
P.6.090 Alexithimia anxiety and depression in patients with bronchial asthma by A. Karkanias; G. Moussas; D. Stamouli; A. Tselebis; Th. Bakogianni (S464).
P.6.086 Functional lateralization of cholinergic neurotransmitter system but not of nictric oxide mediator system in the hippocampus of adult male rats by Z. Kristofikova; D. Ripova (S462).
P.6.087 Executive functions in remitted schizophrenic patients: A preliminary study by G. Saba; C.M. Verdon; V. Moulier; G. Dumortier; K. Kalalou; J.F. Rocamora; R. Benadhira; L. Stamatiadis; D. Januel (S462-S463).
P.6.088 Venlafaxine treatment of depression in schizophrenia: An eight-case report by O. Aydemir; A. Esen-Danaci (S463).
P.6.089 Chromosome 3q29: Follow-up linkage analysis in schizophrenia and bipolar disorder by A. Schosser; K. Fuchs; F. Leisch; U. Bailer; S. Kasper; W. Sieghart; K. Hornik; H.N. Aschauer (S463-S464).
P.6.072 Placebo-controlled study of once-daily atomoxetine in the school setting by M. Weiss; R. Tannock; C. Kratochvil; D. Dunn; J. Velez-Borras; C. Thomason; L. Lambrecht; R. Tamura; D. Kelsey; A.J. Allen (S456-S457).
P.6.071 Structural brain abnormalities in obsessive-compulsive disorder (OCD) by T. Sobanski; G. Wagner; U. Gruhn; A. Herwig; R. Tauber; G. Peikert; H. Sauer (S456).
P.6.055 Nettrocognitive functioning and theory of mind in schizophrenia by R. Herold; T. Tényi; M. Simon; M. Trixler (S449).
P.6.054 Treatment of attention-deficit/hyperactivity disorder with the once daily OROS formulation of methylocnidate: Effect on growth in children by J. Biederman (S448-S449).
P.6.056 Minor physical anomalies in Tourette syndrome by T. Tényi; J. Gádoros; G. Csábi; S. Jeges; E. Gyenge; M. Trixler (S449-S450).
P.6.057 Effects of 2A receptor challenge by psilocybin on cognitive performance and neuroendocrine measures in healthy humans: A serotonin model of psychosis by F. Hasler; U. Grimberg; M.A. Benz; F.X. Vollenweider (S450).
P.6.058 Treatment of auditory phantom perception (tinnitus) with neuronavigated repetitive transcranial magnetic stimulation (rTMS) — a pilot study by B. Langguth; P. Eichhammer; T. Kleinjung; J. Marienhagen; G. Hajak (S450).
P.6.053 Effectiveness and safety of the once-daily OROS formulation of methylphenidate in adolescents with attention-deficit/hyperactivity disorder by J. Biederman (S448).
P.6.052 Evaluation of once-daily OROS methylphenidate in children with attention-deficit/hyperactivity disorder Effects on sleep, approach and tics by J. Biederman (S447-S448).
P.6.047 No association between DRD2 and DRD3 gene polymorphism and bipolar affective disorder by M. Kosmowska; M. Skibinska; M. Kaczmarkiewicz-Fass; A. Leszczynska-Rodziewicz; P. Kapelski; P. Czerski; J. Rybakowski; J. Hauser (S446).
P.6.048 BDNF Val66Met polymorphism in bipolar affective disorder and schizophrenia — association with early age of onset in schizophrenia by M. Skibinska; P. Czerski; A. Leszczynska-Rodziewicz; M. Kosmowska; P. Kapelski; J. Hauser; J. Rybakowski (S446).
P.6.049 General practitioners' attitudes towards psychotic disorders and their treatment in primary health care system in Turkey by M. Yildiz; M.E. Onder; U. Tural; H.I. Balta; N. Kocalim (S446-S447).
P.6.050 Tramadol in the treatment of persistent pain in the elderly by M. Prostran; L.B. Jovanovic; L.J. Zikic; S. Vuckovic (S447).
P.6.059 Leptin and glucose metabolism in eating disorders by A. Gáti; F. Tury; I. Wittmann (S450-S451).
P.6.060 Influence of psychopharmacologic treatment on short-term actigraphic measurements by D. Winkler; E. Pjrek; L. Pezawas; A. Konstantinidis; O. Presslich; J. Tauscher; S. Kasper (S451).
P.6.067 Retrospective chart review of patients with bipolar affective disorder in the community psychiatry setting by R. McIntyre; R. Riccardelli; C. Finder (S454).
P.6.068 Once-daily atomoxetine in childhood ADHD: Continuous symptom relief by A.J. Allen; D. Kelsey; C. Sumner; V.K. Sutton; J. Gonzales; S. Malcolm; K. Schuh; D. Michelson (S454-S455).
P.6.069 The effect of ginkgo biloba extract (GBE) on cognitive and psychomotor performance in healthy young and old volunteers: A meta-analysis by L. Trick; J. Boyle; I. Hindmarch (S455).
P.6.070 Atomoxetine in the long-term prevention of relapse in ADHD by D. Michelson; J. Buitelaar; M. Danckaerts; C. Gillberg; T.J. Spencer; A. Zuddas; S. Zhang; J. Biederman (S455-S456).
P.6.066 Effects of risperidone versus placebo on aggression in children with disruptive behaviour disorders by C. Binder; H. Hew; V. Kusumakar; J. LeBlanc; J. Wang (S453-S454).
P.6.065 MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding potentials by P. Rosa-Neto; A.K. Olsen; S.B. Jensen; O.L. Munk; H. Watanabe; A. Gjedde; P. Cumming (S453).
P.6.061 Treatment of children with attention deficit/hyperactivity disorder: Evaluating switch from conventional methylphenidate to the once-daily OROS formulation of methylphenidate by P. Santosh (S451-S452).
P.6.062 Treatment of children with attention-deficit/hyperactivity disorder for up to one year with the once-daily OROS formulation of methylphenylate: Safety and efficacy by P. Santosh (S452).
P.6.063 COMT haplotypes in schizophrenia by P. Sand; P. Eichhammer; A. Putzhammer; M. Albus; D. Wildenauer; M. Borrmann-Hassenbach; S. Schwab; P. Dallinger; B. Langguth; G. Hajak (S452).
P.6.064 Evaluating venlafaxine treatment for chronic pain by M. Demitrack; N. Kunz; A.R. Entsuah (S452-S453).
P.5.046 Mirtazapine and venlafaxine administration in alcohol detoxification: Impact on anxiety and depression symptoms by E. Tzavellas; J. Liappas; C. Kontoangelos; T. Paparrigopoulos; G.N. Christodoulou (S425-S426).
P.5.045 Effects of venlafaxine on ethanol withdrawal syndrome in rats by E. Saglam; H. Kayir; T. Çelik; M. Beyazyurek; I.T. Uzbay (S425).
P.4.034 Neuropsychiatric symptoms in APOE genotyped Alzheimer's disease patients: Contributions to diagnosis and prognosis of the disease by A. Alvarez; M. Laredo; V. Couceiro; L. Fernandez-Novoa; C. Sampedro; R. Cacabelos; M. Vargas; M. Aleixandre (S399-S400).
P.4.033 Phospholipase D platelet activity in patients with dementia and acute ischaemic stroke by E. Krzystanek; G. Opala; H.I. Trzeciak; M. Krzystanek; J. Suida (S399).
P.4.035 Effects of cerebrolysin on quantitative EEG activity in elderly controls and in patients with brain damage by A. Alvarez; C. Sampedro; M. Laredo; V. Couceiro; P. Perez; R. Cacabelos; H. Moessler; E. Doppler (S400).
P.4.036 Efficacy of rivastigmine on cognitive symptoms and daily living activity in patients with mixed dementia by M.D. Gheorghe; A. Baloescu; G. Grigorescu (S400).
P.4.037 Tic reduction in Tourette's disorder with olazapine by K. Naudts; K. Dhondt; A. Sieben; F. Van den Eynde; K. Audenaert; C. Van Heeringen (S400-S401).
P.4.032 Cognitive influence of topiramate in children by F.J. Quin; G.Gutierrez del Alamo; M.J. Rebollo; P. Corredoira; R.I.Largo Gomez; E.Baca Garcia; F.J. Quintero Lumbreras (S398-S399).
P.4.031 Cerebrovascular reactivity in dementia of Alzheimer's type assessed by acetazolamide SPECT by Y.M. Choi; D.W. Lee (S398).
P.4.026 Hippocampal galanin and acetylcholine in spatial learning of the rat by E. Elvander; T. Yoshitake; J. Kehr; J. Sandin; S.O. Ögren (S396-S397).
P.4.027 In vitro characterization of 2-butyl-9-metyl-8-(2H-1,2,3,-triazol-2-yl)-9H-purin-6-ylamine (ST1535), a novel selective adenosine A2a receptor ligand by M.A. Di Cesare; M. Castorina; F. Giorgi (S397).
P.4.028 Efficacy of bio-normalizer in stroke patients: EEG-mapping, neuropsychological and clinical study by L. Zhavoronkova; O.A. Maksakova (S397-S398).
P.4.030 Pharmacokinetic study of memantine and donepezil in healthy young subjects by A. Periclou; D. Ventura; T. Sherman; N. Rao; H. Mengel; W. Abramowitz (S398).
P.4.038 The 5-HT1A receptor antagonist robalzotan facilitates passive avoidance retention in male mice: Possible mediation via increased cholinergic transmission by N. Madjid; F. Asadi-kanari; J. Sandin; S.O. Ögren (S401).
P.4.039 In vivo characterization of a novel compound 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-ylamine (ST 1535), a selective adenosine A2A antagonist by M.A. Stasi; M.P. Di Pasquale; M.A. Di Cesare; P. Minetti; L. Pacifici; P. Carminati (S401-S402).
P.4.046 Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial by W. Kozubski; S. Hasselbalch; G. Jakab; C.J. Kalisvaart; A. Kurz; J. McCarthy; E. Triau; M. Tsolaki; L. Bergendorff; Y. Xu; N. Kumar; S. Richardson; P. Johannsen (S405).
P.4.047 Memory deficits and neuropathology induced by central amyloid-beta injections in rats by A. Alvarez; C. Sampedro; R. Cacabelos (S405).
P.4.048 CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes expressions in the peripheral blood of Alzheimer's disease (AD) patients by A. Alvarez; V. Lombardi; L. Fernandez-Novoa; I. Echevarria; S. Seona; R. Cacabelos (S406).
P.4.049 The key role of general practitioning treating Alzheimer's disease by D. Keohane; C. Stave (S406).
P.4.045 Dementia patients with additional parkinsonian symptoms benefit from donepezil therapy by J. Kohler; K. Jendroska; R. Horn; M. Kamleiter; J. Möbius; M. Reipe (S404-S405).
P.4.044 Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study by B. Winblad; A. Wimo; A.-L. Wetterholm; A. Haglund; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; R. Zhang; L. Burger; R. Schindler (S404).
P.4.040 Donepezil has significant functional and behavioral benefits in patients with severe Alzheimer's disease by H. Feldman; S. Gauthier; J. Hecker; B. Vellas; Y. Xu; J. Ieni; E. Schwam (S402).
P.4.041 Donepezil is a well-tolerated long-term treatment for patients with mild to moderate Alzheimer's disease: Results from a patient cohort who completed a one-year placebo-controlled study and participated in a two-year follow-up study by B. Winblad; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; A. Wimo; A.-L. Wetterholm; A. Haglund; R. Zhang; L. Burger; R. Schindler (S402-S403).
P.4.042 Gene expression profiling of Alzheimer's lymphocytes by J. Kálmán; A. Zvara; K. Kitajka; A. Juhasz; M. Pakaski; L. Puskas; Z. Janka (S403).
P.4.043 DemTect: Final English version of a new cognitive screening test for mild cognitive impairment and early dementia by J. Kessler; E. Kalbe; P. Calabrese; B. Smith; P. Passmore; R. Bullock (S403-S404).
P.4.025 Benign brain tumours and psychiatric morbidity by R.K. Gupta (S396).
P.4.024 Broad spectrum of clinical benefits from galantamine confirmed in large-scale observational study of Alzheimer's disease in Switzerland by C. Held (S395-S396).
P.4.008 Effects of galanthamine and donepezil on model of aging brain in rats by D. Dimitrova; D. Getova (S389-S390).
P.4.007 Pharmacological study of the interactions between GABA-ergic and glutamate-ergic neurotransmission on cognitive functions and seizure excitability by V. Spassov; D. Getova (S389).
P.4.009 Cholinesterase inhibitors reduce the risk of institutionalization in patients with dementia in a naturalistic treatment setting by D. Luong; R. Sambrook; A. Yu (S390).
P.4.010 Effects of galantamine on the motor and avacuative functions of rat's gastrointestinal tract. In Vivo and in vitro study by A. Krastev; V. Turiiski; V. Sirakov; D. Getova (S390-S391).
P.4.011 Dependence in alzheimer's disease is a clinical and socio-economic relevant outcome by A. Dresse; B. Rive (S391).
P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease by H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody (S388-S389).
P.4.005 Functional improvement from treatment with the NMDA antagonist memantine: Results of a 28-week, randomized, placebo-controlled study in advanced Alzheimer's disease by H.-J. Moebius; D. Galasko; B. Reisberg (S388).
P.4.001 Faster forgetting of spatial memory in the PDAPP mouse-model of Alzheimer's disease by J. Sandin; G. Chen; S.J. Martin; K.S. Chen; R.G.M. Morris (S386-S387).
P.4.002 A retrospective analysis of electrocardiograms of patients treated with donepezil by L. Froelich; F. Heinrich; M. Metz; C. Goebel (S387).
P.4.003 Multi-segmental late onset idiopathic dystonia presenting as tardive dyskinesia and treated with quetiapine by T.D. Mayze; J. O'Sullivan (S387-S388).
P.4.004 Moderately elevated plasma homocysteine and methylenetetrahydrofolate reductase genotype and risk for mild cognitive impairment and Alzheimer's disease by T. Gabryelewicz; M. Styczynska; D. Religa; B. Peplonska; A. Pfeffer; B. Wasiak; M. Barcikowska (S388).
P.4.012 Effect of memantine on levels of the amyloid beta peptide in cell cultures by D.K. Lahiri; G.M. Alley; C. Morgan; P. Banerjee; M. Farlow (S391).
P.4.013 GSK3β over-expressing mice - a mouse model for Alzheimer's disease? by P.A. Schött; A. Rask; Y. Nilsson; A. Staflund; R.V. Bhat (S391-S392).
P.4.020 Efficacy and tolerability of memantine in nursing home patients with moderate to severe dementia of the Alzheimer's type by B. Winblad; G. Lee; H.-J. Möbius; S. McDonald; S. Graham (S394).
P.4.021 Acetylcholinesterase inhibitor, donepezil, is a potent antagonist of potassium channels of neuronal membrane by E. Solntseva; J.V. Bukanova (S394-S395).
P.4.022 Effects of subacute immobilisation stress on infarct volume after experimental stroke in rats by J.C. Leza; J.M. Caso; J.L.M. Madrigal; A. Cárdenas; J.M. Pradillo; P. Lorenzo; I. Lizasoain; J.C. Leza; M.A. Moro (S395).
P.4.023 The peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone decreases neuroinflammatory mediators in brain after stress in rats by J.C. Leza; B. García-Bueno; J.M. Caso; J.L.M. Madrigal; C. Romera; M.A. Moro; I. Lizasoain; P. Lorenzo; J.C. Leza (S395).
P.4.019 Changes in quality of life among schizophrenia patients over one year after a first hospitalization by K. Górna (S394).
P.4.018 Memantine restores okadaic acid-induced changes in the activities of protein phosphatase-2A, CaMKII and hyperphosphorylation of tau in rat hippocampal slices in culture by K. Iqbal; L. Li; A. Sengupta; I. Grundke-Iqbal (S393-S394).
P.4.014 Correlation of depressive symptoms and cognitive decline in elderly people by I.-K. Jung (S392).
P.4.015 A 6 month follow-up of cognitive function in urban community older people by J.W. Yang; I.-K. Jung; Y.J. Seo (S392).
P.4.016 Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer's disease by H. Tanila; R. Minkeviciene; P. Banerjee (S392-S393).
P.4.017 Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease by G. Grossberg; P. Tariot; M. Farlow; I. Gergel; S. Graham; J. Jin (S393).
P.4.050 Homocysteine induces cell death of astrocytes in vitro by M. Maler; J. Wiltfang; D. Degner; J. Kornhuber; S. Bleich (S406).
P.4.051 Cognition is physicians' main indicator of treatment efficacy in Alzheimer's disease patients by E. Triau; R. Heun; R. Holub; S. Jakobsen; I. Kloszewska; F. Tury; V. Vagenas; F.R.J. Verhey; S. Qvitzau; S. Richardson; Y. Xu; E. Schwam; R. Schindler; P. Johannsen (S407).
P.5.029 Legal complications of bipolar disorder accompanied by alcohol, cannabis, or cocaine abuse or dependence by J. Calabrese; M. Shelton; O. Elhaj; D. Rapport; K. Sak-Jackson; E. Youngstrom; K. Packer; S. Bilali; R. Findling (S419).
P.5.028 Estimates of illicit drug use during pregnancy by maternal interview and meconium analysis by C. Mortali; E. Marchei; M. Pellegrini; E. Perez-Alarcòn; C. Puig; O. Vall; R. Pacifici; L. Ordobas; S. Pachini; O. Garcia-Algar (S419).
P.5.030 Substance use disorders and their treatment response in dual diagnosis bipolar disorder by J. Calabrese; M. Shelton; O. Elhaj; D. Rapport; E. Youngstrom; K. Packer; K. Sak-Jackson; S. Bilali; R. Findling (S419-S420).
P.5.031 Tryptophan hydroxylase polymorphism, family history, and severity of illness are associated with age of alcoholism onset in a Korean population by I.W. Chung; H. Kim; W. Sribney; J.B. Hong; C.H. Lee; K.Y. Lee; H.M. Nan; Y.S. Kim; P. Manowitz (S420).
P.5.032 Involvement of 5-HT1 and 5-HT2 receptor in regulation of methamphetamine self-administration in rats by J. Novakova (S420).
P.5.027 C-fos expression after cocaine or morphine sensitization in CB1 knockout mice by P. Murtra; M. Martin; C. Ledent; M. Patmentier; R. Maldonado (S418-S419).
P.5.026 Rates of lifetime and current use of cannabis, inhalants and other illicit drugs in three different age groups in Turkey by S. Tot; K. Yazici; A. Yazici; P. Erdem; N. Bal; O. Metin (S418).
P.5.022 5-HTT gene polymorphism in Korean alcoholics by C.-T. Lee (S417).
P.5.023 The effects of cannabinoid CB1 receptor antagonist AM 251 on locomotor/exploratory behaviour and body weight in mice by K. Slais; L. Landa; A. Sulcova (S417).
P.5.024 Rates of lifetime and current cigarette and alcohol use in three different age groups in Turkey by K. Yazici; S. Tot; A. Yazici; O. Metin; N. Bal; P. Erdem (S417).
P.5.025 Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis by H. Ujike; M. Harano; T. Inada; M. Yamada; T. Komiyama; Y. Sekine; I. Sora; M. Iyo; T. Katsu; A. Nomura; K. Otani; Y. Morita; N. Ozaki; S. Kuroda (S418).
P.5.033 Apolipoprotein E epsilon 4 is associated with hippocampal volume reduction in females with alcoholism by S. Bleich; J. Wilhelm; D. Degner; W. Sperling; J. Kornhuber (S420-S421).
P.5.034 Do women have more risk of relapse than men in primary alcoholism? by D. Marra; D. Warot; I. Berlin; E. Hispard; C. Notides; C. Payan; J.F. Allilaire; J.P. Lépine; S. Dally; H.J. Aubin (S421).
P.5.041 Differential actions of nicotinic agonists on exploratory behaviour in rats by N. Moore; R. Nunan; C. Greenhalgh; G. Rees; B. Tree (S423-S424).
P.5.042 Assessment of substance abuse in acute admission to psychiatric care by J.C. Flovig; G. Morken; A.E. Vaaler (S424).
P.5.043 Schizotypy and memory deficits linked with ketamine dependence by K. Jansen; R. Darracott-Cankovic; C. Chandler; L. Theron (S424).
P.5.044 Genetic polymorphisms of alcohol and aldehyde dehydrogenase, dopamine and serotonin transporters in alcohol dependence patients with or without family history of alcohol dependence by I.G. Choi; H.G. Son (S425).
P.5.040 Thyreotropin-releasing hormone and cocaine sensitization in rats by M. Filip; K. Czepiel; E. Nowak; K. Wydra; E. Przegaliński; W. Lasoń (S423).
P.5.039 Influence of serotonin 5-HT2A and 5 HT2C receptor agonists and antagonists on the locomotor and discriminative stimulus effects of cocaine or direct dopamine D1-like and D2-like receptor agonists by M. Filip; K.A. Cunningham (S422-S423).
P.5.035 Frequency and causes of premature termination during in-patient opiate detoxification by A. Heiden; C. Baecker; R. Frey; O. Presslich; S. Kasper (S421).
P.5.036 Dependence on tramadol — a case series by A. Paiva; M. Lobo; J. Chainho (S421-S422).
P.5.037 Craving treatment: The role of citalopram and paroxetine by M. Campana; M. Riglietta; A. Crocco; M. Nava (S422).
P.5.038 Topiramate in benzodiazepine withdrawal by D.F. Zullino; A. Miozzari; R. Rajeswaran; Y. Khazaal; G. Zimmermann; S. Krenz; J. Besson (S422).
P.5.021 Inhibition of cannabinoid CB1 receptor attenuates behavioural sensitization to methamphetamine in mice by L. Landa; K. Slais; A. Sulcova (S416-S417).
P.5.020 Patterns of drug consumption in first-episode drug-naive schizophrenic patients by L. San; B. Arranz; N. Ramirez; R. Dueñas; J.M. Sanchez; L. Miralles; M. Berrospi (S416).
P.5.004 Changes of smoking behavior and serum levels of endogenous opioids and prolactin in nicotine dependents with naltrexone treatment by I.K.S. Young Sik Lee (S410).
P.5.003 Metoclopramide and ondansetron prn during multidrug withdrawal by A. Miozzari; R. Rajeswaran; G. Zimmermann; S. Krenz; D.F. Zullino (S409-S410).
P.5.005 Lack of relationship between DRD2 and DAT polymorphisms and dopaminergic activity assessed by the apomorphine challenge by E. Pinto; J. Reggers; M. Hansenne; W. Pitchot; S. Fuchs; P. Gorwood; D. Vaira; M. Ansseau (S410).
P.5.006 Evaluation of using the biological markers ethyl glucuronide, carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume as an indicator of alcohol abuse and abstinence by A. Emara (S410-S411).
P.5.007 Fagerström tolerance questionnaire, time to first cigarette of the day, craving/withdrawal symptoms by V. Teneggi; L. Squassante; L. Ziviani; S. Milleri; A. Bye (S411).
P.5.002 The effects of beta-adrenergic receptors on the acquisition of nicotine-induced conditioned place preference in mice by H. Zardooz; H. Sahraei; S. Oryan; M.R. Zarrindast; L. Hossein-Mardi (S409).
P.5.001 Effects of nitric oxide in the CA1 area of the hippocampus of rat on conditioning place preference of morphine by H. Sahraei; M.R. Zarrindast; H. Sepehri; M. Karami (S409).
P.4.052 Phosphatidylserine (BCPS) did not reverse the memory impairment associated to intranigral MPTP lesion in rats by R. Andreatini; J.C. Perry; M.A.B.F. Vital; J. Anselmo-Franci; C. Da Cunha; S. Tufik; E. Miyoshi (S407).
P.4.053 Vinpocetine selectively increases vigilance in healthy young subjects by Z. Tokaji; J. Kálmán; A. Pestenácz; L. Oroszi (S408).
P.4.054 Modulating effect of EGCG upon glutamate induced calcium increase in PC12 cells by J.H. Lee; C.-H. Jung; D.-K. Song; J.-H. Bae (S408).
P.4.055 Neurological development of infants exposed to benzodiazepines in utero by N. Cerovac Cosic; M. Proçtran; N. Jovic; S. Gligorovic; S. Todorovic (S408-S409).
P.5.008 Association study between the dopamine D4 receptor gene and Korean alcoholism by S.-H. Ryu; M.-S. Lee (S411).
P.5.009 Buprenorphine: A new pharmacological option for heroin addicts' treatment by L. Guglielmino; P. Vigezzi; R. Silenzio; M. De Chiara; F. Corrado; P. Marzorati; L. Cocchi; E. Cozzolino (S411-S412).
P.5.016 Effects of nitric oxide synthase inhibitor L-NOARG on behaviour in mice after chronic ethanol inhalation by P. Pokk; K. Õkva; A. Lang; E. Sepp; M. Väli; T. Nevalainen (S414-S415).
P.5.017 Medications in development to treat stimulants addiction: Update from NIDA/DTRD by A. Elkashef; F. Vocci (S415).
P.5.018 Temperamental traits in multiaddictive behaviors by A. Dervaux; F.J. Bayle; M.O. Krebs; M. Lejoyeux; J. Adès (S415-S416).
P.5.019 Methylphenidate replacement: A long-term treatment of non-comorbid amphetamine abusers? by X. Laqueille; A. Dervaux; F. El Omari; M. Kanit; F.J. Baylé (S416).
P.5.015 Possible involvement of COX2 in the expression of morphine withdrawal by R. Farina; W. Milano; C. Petrella; A. Capasso (S414).
P.5.014 Diazepam in combination with piracetam in the treatment of alcohol withdrawal syndrome by V. Lazarova; M. Jakovcevska-Kujundziska; V. Filovska (S413-S414).
P.5.010 Effect of naltrexone on conditioned physiological responses induced by alcohol related cue in the alcoholics by S.-G. Kim; Y.-S. Song; C.-J. Kang; J.-M. Park; M.-J. Kim (S412).
P.5.011 Individual reactivity to a novel environment predicts differences in anxiety-like behaviours and in morphine-induced locomotor sensitisation and tolerance in the rat by M. Kalinichev; D.A. White; S.G. Holtzman (S412-S413).
P.5.012 The role of muscarinic receptors in the control of acute morphine withdrawal by A. De Iovanna; W. Milano; C. Petrella; A. Capasso (S413).
P.5.013 Health, general functioning and psychopathology in patients treated with methadone and LAAM by F. Cavaglia; N. Gonçalves; G. Borges; D. Pires-Barreira; A. Matos-Pires (S413).
P.2.042 The quality of life in schizophrenia and atypical antipsychotics by D.M. Podea (S297).
P.2.041 High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia by M. Ermilov; D.C. Javitt; P. Lichtenberg; G. Bar; U. Heresco-Levy (S296-S297).
P.1.018 Cross-sectional assessment of psychiatric morbidity, satisfaction with life and perceived social support in renal transplantation patients in Turkiye; a preliminary study by A. Soykan; B. Arapaslan; H. Kumbasar (S182-S183).
P.1.017 Which GP deals better with depressed patients in primary care in Turkiye; “interested in psychiatry” and/or “continuously educated”? by A. Soykan; B. Oncu (S182).
P.1.019 Depression in chronic viral hepatitis patients during long-term treatment with interferon alpha — use of tianeptine by N. Ivanets; M.A. Kinkulkina; A.O. Morozov (S183).
P.1.020 A whole gene based SNP study of the AVP 1B receptor gene: A possible protective effect in the etiology of major depression by D. Van West; J. Del Favero; Y. Aulchenko; D. Souery; J. Mendlewicz; R. Adolfsson; D. Deboutte; C. Van Duijn; C. Van Broeckhoven; S. Claes (S183).
P.1.021 The effects of venlafaxine on behavioural effects in chronically stressed rats by E. Nowakowska; K. Kus; T. Bobkiewicz-Kozłowska (S183-S184).
P.1.016 In vivo pharmacology of AZD1134, a novel 5-HT1B antagonist by T. Hudzik; J. Smolka; L. Litwin; T. Porrey; E. Pierson (S181-S182).
P.1.015 Development of weight in depressive patients treated with thymoleptic medication by P. Debbelt; U. Trenckmann (S181).
P.1.011 Meta-analysis of efficacy of two pilot clinical studies with a novel pentapeptide antidepressant, nemifitide, in the treatment of depression by S.A. Montgomery; J.P. Feighner; L. Sverdlov; H. Abajian; J. Hlavka; G. Nicolau; J. Freed (S179-S180).
P.1.012 Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration by Y. Osher; B.A. Sela; J. Levine; R.H. Belmaker (S180).
P.1.013 Serum thyroid-stimulating-hormone (TSH) in major depression: Relevance of “high normal” concentrations by E. Corruble; I. Berlin; A. Lemine; P. Hardy (S180-S181).
P.1.014 The pharmacokinetics of fluoxetine in elderly volunteers ages 65–85 by J. Ferguson; H. Hill (S181).
P.1.022 Olanzapine-SSRI in the treatment of major depressive episode with somatoform symptoms by A.M. Iordache; G. Cicu; N. Marcu; M. Sobescianschi; R. Rascu (S184).
P.1.023 Antidepressants combination. How and when use them? by L.Agüera Ortiz; J.Gandara Martin; E.Rojo Rodes (S184).
P.1.030 Regulation of brain-derived neurotrophic factor expression by phosphokinase A activity in lymphoblast cells of bipolar disorder and control subjects by F. Karege; R. El Kouaissi; M. Schwald (S187).
P.1.031 Gepirone extended release (ER) in patients with anxious depression by M. Fava; J. Alpert; C. Kremer (S187-S188).
P.1.032 Relapse prevention with gepirone ER in outpatients with major depression by F. Ruwe; M. Gibertini (S188).
P.1.033 Analysis of gepirone ER on the bech-6 and individual hamD-17 item scores by A.J. Schutte; M. Gibertini; J.H. Simmons (S188).
P.1.029 The prevalence and clinical characteristics of depression in selected school-based study in Mersin in Turkey by A.Ertekin Yazici; F. Toros; N.Gamsiz Bilgin; R. Bugdayci; T. Sasmaz; H. Camdeviren; A.Yazici Ertekin (S187).
P.1.028 Typical neuroleptics versus atypical antipsychotics in the treatment of acute mania in a natural setting by M. Letmaier; D. Schreinzer; L. Reinfried; G. Glauninger; N. Thierry; T. Kapitany; S. Kasper (S186).
P.1.024 Clinical application of low cholesterol as an indicator of suicidal risk in major depression by Y. Kim (S185).
P.1.025 Fluvoxamine response in nondemented elderly compared to younger depressives by D. Rossini; C. Cusin; D. De Ronchi; A. Serretti; R. Zanardi (S185).
P.1.026 Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and healthy controls by N. Thierry; M. Willeit; N. Praschak-Rieder; P. Zill; K. Hornik; A. Neumeister; E. Hilger; S. Kasper (S185-S186).
P.1.027 Pharmacological study of memory enhancing effects of the antidepressant drug moclobemide by D. Getova; D. Dimitrova; I. Roukounakis (S186).
P.1.010 The diagnosis of bipolar II disorder by F. Benazzi (S179).
P.1.009 Temperamental mood lability and depressive mixed states by F. Benazzi (S178-S179).
S.27.03 The D3 receptor gene and the pharmacogenetics of tardive dyskinesia by B. Lerer (S168-S169).
S.27.02 A partial D3 receptor agonist in schizophrenia by Y. Lecrubier (S167-S168).
S.27.04 Dopamine D3 receptor in Parkinson's disease and schizophrenia by J. Joyce (S169-S170).
S.27.05 Nicotine and dopamine D3 receptor: Implications in drug addiction and Parkinson's disease by B. Le Foll; J. Diaz; J.-C. Schwartz; P. Sokoloff (S170).
S.28.01 5-HT approaches to anxiety: Making sense of animal studies by P.J. Mitchell (S171-S172).
S.27.01 The dopamine D3 receptor as a therapeutic target by J.-C. Schwartz (S166-S167).
S.26.05 Environmental and genetic risk factors in schizophrenia on ‘cognitive and social function as endophenotypes’ by M. Davidson; M. Weiser; A. Reichenberg; J. Rabinowitz; H. Knobler (S166).
S.25.02 Pharmacological interventions in affective disorder by D. Baldwin (S163).
S.25.03 Reducing risk of suicide in schizophrenia by H.Y. Meltzer (S163-S164).
S.25.04 Non-pharmacological prevention of suicidal behaviour by Z. Rihmer (S164-S165).
S.26.03 Schizophrenia genes identified by positional cloning affect the glutamatergic system by H. Stefansson; E. Sigurdsson; V. Steinthorsdottir; J.R. Gulcher; H. Petursson; K. Stefansson (S165-S166).
S.28.02 Neuropeptide Y (NPY) in anxiety, depression and alcohol dependence by M. Heilig (S172).
S.28.03 Facilitation of fear extinction by NMDA agonists by M. Davis (S172-S173).
P.1.005 The serum cytokines and nutritional status after antidepressant treatment in hemodialysis patients by S.-K. Lee; J.-R. Koo; D.-H. Kim; B.-K. Son (S177).
P.1.006 Antimanic efficacy of topiramate as monotherapy for bipolar I disorder, most recent episode manic or mixed: A pilot study in Korea by D.H. Kwon; B.H. Chuan; S.N. Cho; H.T. Kim (S177).
P.1.007 A prospective trial of adjunctive short-term hormone replacement therapy to antidepressant treatment in postmenopausal women with depression by S.H. Joe; J.W. Kim; S.H. Kim; I.G. Jung; H.S. Lee (S177-S178).
P.1.008 Lifetime prevalence of manic/hypomanic syndromes in young adults by F. Benazzi (S178).
P.1.004 Repetitive transcranial magnetic stimulation (rTMS) as an add-on therapy in depression: A prospective, monocenter, randomized, double-blind, sham controlled trial by M. Walpoth; A. Hausmann; S. Mechtecheriakov; K. Kramer-Reinstadler; T. Lechner; T. Walch; E. Deisenhammer; G. Kemmler; C. Rupp; M. Kofler; H. Hinterhuber; A. Conca (S176-S177).
P.1.003 Lithium, but not valproate increases NAA concentrations in bipolar patients: An MRS study by P. Silverstone; R.H. Wu; T. O'Donnell; M. Ulrich; S.J. Asghar; C.C. Hanstock (S176).
S.28.05 Antidepressant mechanisms in anxiety disorders by D.J. Nutt; J.R. Nash; C. Bell; M. Adrover; P.A. Sargent; E.A. Rabiner; S. Hood; S. Argyropoulos; P. Grasby (S173).
P.1.000 Sex differences in stress-induced depression by M.D. Jones; I. Lucki (S175).
P.1.001 Lithium attenuates the effects of dextro-amphetamine in volunteers: An fMRI study by P. Silverstone; M. Wilson; A. Wilman (S175).
P.1.002 The relationship between the Serum cytokine and clinical improvement in major depressive disorder by H.C. Kim (S176).
P.1.034 Chronic gepirone treatment alters regional 5-HT1A receptor coupling efficiency in rat brain by N. Ward; P. Wren; B. Henry; S. McElroy; G. Walker; O. Epemolu; J. Van Kalkeren; D.R. Hill (S188-S189).
P.1.035 Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment by M. Wohlreich; S. Brannan; C. Mallinckrodt; M. Detke; Y. Lu; J. Watkin; G. Tollefson (S189).
P.1.069 Metyrapone in the treatment of major depression: Efficacy and endocrine changes during steroid-synthesis inhibition by H. Jahn; F. Kiefer; J. Arlt; K. Wiedemann; M. Schick (S204).
P.1.067 Bipolar disorder: One year follow-up study by M. Can Saka; S. Ozer; A. Ulusahin (S203).
P.1.070 The R-enantiomer of citalopram counteracts escitalopram-induced in vivo effects in rats by A. Mork; C. Sánchez (S204).
P.1.071 R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model by M. Papp; P. Gruca; E. Bien; C. Sánchez (S204-S205).
P.1.072 The effect of venlafaxine treatment on the bereitschaftspotential in depressed patients by A.S. Gonul; C. Suer; A. Oguz; C. Ozesmi (S205).
P.1.066 The effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients by A.S. Gonul; F. Akdeniz; F. Taneli; O. Donat; C. Eker; S. Vahip (S203).
P.1.065 Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain by A. Ortega-Alvaro; I. Acebes; G. Saracibar; E. Echevarría; L. Casis; J.A. Micó (S202-S203).
P.1.061 Characteristics of attenders and non-attenders at a bipolar disorder psycho-education programme by C. Even; H. Richard; M. Kalck-Stern; S. Friedman; J.D. Guelfi (S200-S201).
P.1.062 Naturalistic study of outcome of mood stabilizing treatment in bipolar disorder by J.S. Garnham; A. Munro; A. Teehan; C. Slaney; A. Duffy; M. MacDougall; M. Passmore; M. Alda (S201).
P.1.063 Effect of sub-chronic treatment with jarsin (extract of St John's wort) at two doses on evening salivary cortisol and melatonin in healthy male volunteers by M. Franklin; A. Reed; H. Murck (S201-S202).
P.1.064 Differential response to imipramine in mice lacking D2 or D4 dopamine receptor gene by M.O. Rojas-Corrales; E. Berrocoso; A.B. Martin; D. Grandy; J.A. Micó; R. Moratalla (S202).
P.1.073 R-citalopram functionally antagonizes escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporter by S. Stórustovuí; C. Sánchez; P. Pörzgen; L.T. Brennum; A.K. Larsen; M. Pulis; B. Ebert (S205-S206).
P.1.074 Changes in glucocorticoid levels within the diurnal range alter α1-adrenoceptor and 5-HT1A receptor modulation of 5-HT neuronal firing by S.J. Judge; C.D. Ingram; S.E. Gartside (S206).
P.1.081 Chronic treatment of various antidepressants increases Golf proteins in the rat nucleus accumbens and striatum by H. Taoka; T. Hamamura; S. Endo; M. Miki; Y. Lee; S. Miyata; T. Ishihara; T. Habara; T. Oka; K. Toma (S209).
P.1.082 Post-stroke model of emotional disturbances: Effects of milnacipran compared to reference compounds by M. Bourin; G.B. Bantsiele; N. Amiot; J.M. Reymann (S209).
P.1.083 Efficacy of citalopram treatment in subjects with burning mouth syndrome with and without depressive disorders by A. Miller; J. Rabe-Jablonska (S209-S210).
P.1.084 Safety of agomelatine in the treatment of depression: Absence of discontinuation symptoms by S.A. Montgomery (S210).
P.1.080 Treatment-seeking behaviors among Korean university women with premenstrual symptoms by J.W. Choi; C.Y. Kim; B.S. Jeong (S208).
P.1.079 Temporal profile of symptom improvement in antidepressant treatment by R. Hirschfeld; T. Burt; E. Batzar; H. Sackeim (S208).
P.1.075 Effect of combined treatment with imipramine and metyrapone on the immunological and endocrine parameters of rats subjected to the forced swimming test by Z. Rogóz; G. Skuza; M. Kubera; A. Basta-Kaim; B. Budziszewska; L. Jaworska-Feil; M. Tetich (S206).
P.1.076 Effect of combined treatment with imipramine and amantadine in patient with drug-resistant unipolar depression — clinical and immunological studies by Z. Rogóz; M. Kubera; A. Basta-Kaim; W. Lasoń; D. Dudek; A. Wróbel; A. Ziȩba (S207).
P.1.077 Long-term use of olanzapine/fluoxetine combination for major depressive disorder: A 76-week study by S. Corya; S. Andersen; H. Detke; L. Van Campen; T. Sanger; D. Williamson; S. Dube (S207).
P.1.078 Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depression by E. Vieta; M. Tohen; T. Ketter; J. Calabrese; S. Andersen; H. Detke; R. Risser; S. Corya (S207-S208).
P.1.060 Flumazenil suppresses microsleep during partial sleep deprivation in patients with major depression and may stabilize the antidepressant effect after the recovery night by E. Holsboer-Trachsler; U. Hemmeter; M. Hatzinger (S200).
P.1.059 EPID — the first epidemiological study on depression in Slovakia pharmacotherapy in depressive patients by V. Novotný; J. Pečeňák; A. Heretik; A. Heretik; A. Ritomský (S199-S200).
P.1.043 Lithium induced alterations in NTP levels in human brain: A proton decoupled 31P MRS study by A. Yildiz; G.S. Sachs; Z. Tunca; C.M. Demopulos; C.M. Moore; P.F. Renshaw (S192-S193).
P.1.042 Thyrotropin-releasing hormone stimulation and dexamethasone suppression tests before and after antidepressant treatment in depressive patients by E. Esel; S. Kartalci; M. Kula; M.T. Turan; Y. Hacimusalar; A. Tutus; M. Basturk (S192).
P.1.044 Amisulpride in combination with maprotiline in the treatment of psychotic depression — a clinical experience by M. Jakovcevska-Kujundziska; V. Filovska; L. Lazarova; R. Krsteska (S193).
P.1.045 Interactions between dopaminergic system and HPT axis in depression: Implication for pathogenesis of suicidal behavior by F. Duval; M.C. Mokrani; J. Monreal; B. Hamel; S. Fattah; J.P. Macher (S193-S194).
P.1.046 Comparison of the safety of two approaches to amitriptyline dose individualization by G. Mihajlovic; D. Milovanovic; D.Ignjatovic Ristic; S. Jankovic; M. Rikanovic (S194).
P.1.041 Growth hormone response to L-DOPA and dexamethasone suppression tests before and after treatment in depressive patients by E. Esel; S. Kartalci; M. Kula; M.T. Turan; Y. Hacimusalar; A. Tutus; S. Sofuoglu (S191-S192).
P.1.040 Combination of mood stabilizer with quetiapine for treatment of acute bipolar disorder: An open label study by W.M. Bahk; K.U. Lee; B.H. Yoon; J.H. Chae; T.Y. Jun; K.S. Kim (S191).
P.1.036 Lack of anti-depressant efficacy of the selective 5-HT1A receptor antagonist NAD-299. Results from an 8-week placebo and paroxetine-controlled study by C. Ybema; F. Unden; S.O. Thorberg; M. Linder; S. Kennedy (S189).
P.1.037 Quality of life post MI: Influence of depression and effect of treatment with sertraline by J.R. Swenson; A.H. Glassman; K. Swedberg; D. Barton; L. Van Zyl; L. Forman; C. O'Connor (S190).
P.1.038 Treatment of bulimia nervosa with sertraline: A randomized controlled trial by C. Sabatino; W. Milano; C. Petrella; L. Milano; A. Capasso (S190).
P.1.039 Depression in the elderly: A comparative and correlational study by A. Matos-Pires; L. Fernandes; D. Pires-Barreira; G. Borges; F. Cavaglia (S190-S191).
P.1.047 Effects of antidepressant treatment on alpha 2-adrenoreceptor function in depressed patients by F. Duval; M.C. Mokrani; J. Monreal; P. Bailey; B. Hamel; J.P. Macher (S194).
P.1.048 Metabolism phenotype and in vitro drug-drug interaction studies with nemifitide, a novel pentapeptide antidepressant by G. Nicolau; J.P. Feighner; P. Silber; G. Chen; H. Abajian; M. Bathala (S194-S195).
P.1.055 Regional cerebral blood flow changes with simple photon emission tomography and tis neuropsychological correlations in bipolar disorders by A. Benabarre; A. Martínez-Arán; F. Colom; D. Muñoz; J.M. Goikolea; B. Corbella; C. Torrent; M. Comes; J. Sánchez-Moreno; F. Lomeña; E. Vieta (S198).
P.1.056 Canadian network for bipolar disorder (CAN-BD): Preliminary report of data on the first 126 patients by L.N. Yatham; P. Silverstone; C. Gorman; P. Baruch; J. Leblanc; P. Cervantes; S. Beaulieu (S198-S199).
P.1.057 Contrasting effects of reboxetine and fluoxetine on regional expression of Fos-like immunoreactivity in the rat forebrain by S. Miyata; T. Hamamura; Y. Lee; M. Miki; T. Habara; T. Oka; S. Endo; H. Taoka; S. Kuroda (S199).
P.1.058 Immunotropic influence of acute or chronic administration of Nootrop on the function of the GABA-ergic system in patients with major depression by S. Minenko (S199).
P.1.054 Effect of combined administration of 5-HT1A or 5-HT1B receptor antagonists and antidepressant drugs in the forced swimming test in rats by E. Tatarczyńska; A. Kłdzińska; K. Stachowicz; E. Chojnacka-Wójcik (S197-S198).
P.1.053 Depressive symptoms and cognitive decline in elderly people by I.-K. Jung; J.W. Yang; Y.J. Seo (S197).
P.1.049 The 5-HTTLPR polymorphism in the SCL6A4 gene is associated with antidepressant induced mania in bipolar disorder by E. Masoliver; A. Menoyo; V. Pérez; E. Grasa; M. Baiget; D. Puigdemont; E. Alvarez (S195).
P.1.050 Subthreshold symptomatology and quality of life in a non psychiatric population: Usefulness of pharmacological treatment by M. Martinucci; A. Goracci; U. Scalcione; P. Castrogiovanni (S195-S196).
P.1.051 Assessment of impulsiveness and aggressiveness in psychiatric disorders: Correlations with general psychopathology and pharmacological treatment implications by M. Martinucci; A. Goracci; A. Mazza (S196).
P.1.052 Lithium-induced psoriasis in bipolar disorder: Importance of common predisposing factors between effective symptomatology and psoriasis by M. Martinucci; A. Boccadamo; M. Di Rienzo; C. Sbaragli (S196-S197).
S.25.01 Psychotropic drugs in the prevention of suicide by G. Isacsson (S162).
S.24.05 Agonist-antagonist binding: Relevance for therapeutic action by D. Hoyer (S161-S162).
S.08.03 mGluR subtypes in neuronal circuits of the primate and rodent brain: Potential morphological substrate for psychiatric disorders by L. Mrzljak (S113-S114).
S.08.01 The metabotropic glutamate receptor progress towards novel therapeutics by D.D. Schoepp; C. Swanson; A. Linden; L. Levine; W. Potter (S113).
S.08.04 Allosteric modulators of mGluR by F. Gasparini (S114-S115).
S.08.05 Metabotropic glutamate receptors in the amygdala and fear by M. Fendt; S. Schmid (S115).
S.09.01 Immunization therapy for Alzheimer's disease by C. Hock; R.M. Nitsch (S115-S116).
S.07.05 Advances in the pharmacogenetic prediction of clozapine response by R.W. Kerwin (S112).
S.07.04 Towards pharmacogenomics: A large-scale association study on response to haloperidol by D. Rujescu; I. Giegling; M. Schafer; N. Dahmen; T. Sander; A. Szegedi; M.R. Toliat; H.-J. Möller; B. Bondy; A.M. Hartmann; H.H. Stassen (S112).
S.06.03 Is dopamine a variable in PET-studies on drug induced receptor occupancy? by L. Farde (S109-S110).
S.06.04 Can we measure 5-HT release with PET? by P.M. Grasby; E. Hirani; S. Hume; P. Cowen; E. Rabiner; T. Sharp (S110).
S.07.01 Functional genomics of schizophrenia: Alterations of specific pathways by K. Mirnics (S110-S111).
S.07.03 Gene expression and neuroleptic drug exposure by P. Falkai (S111).
S.09.03 Statins in the treatment of Alzheimer's disease by K. Beyreuther; T. Hartmann (S116).
S.09.04 Memantine: Treatment opportunity for severe dementia by V. Jelic; B. Winblad (S116-S119).
S.11.02 The amygdala and social cognition by A. Aleman (S123-S124).
S.11.03 Fear, amygdala and the X chromosome by J. Morris; D.H. Skuse; R.J. Dolan (S124-S125).
S.11.04 The amygdala and mood disorders by M. Phillips; N. Lawrence; S. Surguladze; N. Kerr; A. Williams (S125-S126).
S.11.05 Dysfunction and plasticity of amygdala in schizophrenia by F. Schneider (S126).
S.11.01 The amygdala and dopamine by A. Grace; A. Rosenkranz (S122-S123).
S.10.05 Role of 5HT in eating disorders by W. Kaye; G. Frank; N. Barbarich; S. Henry; U. Bailer (S121-S122).
S.09.05 Tau kinase inhibition for treatment of Alzheimer's disease by R. Bhat (S119).
S.10.01 Animal models for eating disorders by R.A.H. Adan; J. Hillebrand; A. Van Elburg; M. Koeners; H. Van Engeland; M.J.H. Kas (S119-S120).
S.10.02 Psychoneuroendocrinological aspects of anorexia nervosa by H. Van Engeland; A. Van Elburg; M. Kas; R.A.H. Adan (S120-S121).
S.10.04 The brain and eating disorders by J. Treasure; R. Uher; I. Campbell (S121).
S.06.02 Imaging dopamine synaptic activity with PET by M. Laruelle (S109).
S.05.05 Chronobiological treatment of bipolar depression by F. Benedetti; C. Colombo; A. Pontiggia; A. Bernasconi; B. Barbini; E. Smeraldi (S108-S109).
S.02.05 The pathophysiology of pain in depression by J.A. Micó; M.O. Rojas-Corrales; E. Berrocoso; J. Elorza (S98-S99).
S.02.04 The impact of depression on the outcome of physical diseases by J.-C. Bisserbe; M. Flament; S. Paterniti (S97-S98).
S.03.01 In vivo and in vitro models of AD demonstrate a role of distinct phosphorylation sites of tau in neurofibrillary tangle formation by F. Chen; A. Schild; P. Kurosinski; L. Pennanen; F. Hoerndli; D. David; A. Ferrari; R.M. Nitsch; J. Götz (S99-S100).
S.03.02 Tau phosphorylation in Alzheimer's disease by D. Hanger (S100).
S.03.03 Characterization and reconstitution of gamma-secretase by H. Steiner; D. Edbauer; K. Shirotani; C. Haass (S101).
S.02.01 Psychological and pharmacological therapies in combination in depression by E. Paykel (S96-S97).
S.01.05 Rational and efficacy of COX-2-inhibitors as adjunctive therapy in schizophrenia by M. Riedel; H.-J. Möller; N. Müller (S96).
L.03 Can the efficacy of drug treatment in depression be augmented by cognitive psychotherapy? by H.-J. Möller (S94).
S.01.01 Antipsychotic effect of four different compounds — results of the metatrial by W. Rein; L. Arvanitis (S95).
S.01.02 Efficacy of partial dopamine agonists by H.-J. Möller (S95-S96).
S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosis by J. Krystal; D.H. D'Souza; D.H. Mathalon; A. Belger; E. Perry (S96).
S.03.05 Protofibrils in the pathogenesis of Alzheimer's disease by L. Lannfelt (S102).
S.04.1 Analysis of cerebrospinal fluid of depressed patients by M. Rosenhagen; D. Milfay; G. Maccarrone; M. Uhr; F. Holsboer; C. Turck (S102).
S.04.08 Expression of endothelin-converting enzyme-1 in human cerebral cortex protects against Alzheimer's disease by B. Funalot; T. Ouimet; A. Claperon; C. Fallet; A. Delacourte; J. Epelbaum; T. Subkowski; J.P. David; P. Amouyel; J.-C. Schwartz; N. Helbecque (S105).
S.05.01 Is bipolar depression a different indication? A European regulatory point of view by K. Broich (S105-S106).
S.05.02 Anticonvulsant prophylaxis in bipolar disorder: Is phenytoin the prototype? by R.H. Belmaker; A. Mishory; Y. Bersudsky (S106-S107).
S.05.04 Inhibition of myo-inositol-phosphate synthase by valproate; a mechanism for mood stabilization? by M.L. Greenberg; D. Ding; G. Shaltiel; S. Ju; G. Agam; R.H. Belmaker (S107-S108).
S.04.07 Role of monoamine oxidase in imidazoline2 binding site mediated function in rat brain by L. Paterson; R.J. Tyacke; E.S.J. Robinson; D.J. Nutt; A.L. Hudson (S104-S105).
S.04.06 Cellular localization of 5-HT1A, 5-HT1B and α1B receptor mRNAs in the raphe nuclei. A double in situ hybridization study throughout the raphe nuclei by J. Serrats; G. Mengod; R. Cortés (S104).
S.04.02 Biochemical modulation of AMPA receptor function by antidepressants by P. Svenningsson; E. Tzavara; G. Nomikos; B. McEwen; P. Greengard (S102-S103).
S.04.03 Endogenous opioid systems and behavioural effects of cocaine: Evidence from ì-opioid receptor knockout and chronic naltrexone treated mice by H. Lesscher; J.M. Van Ree; M.A.F.M. Gerrits (S103).
S.04.04 Analysis of gene expression in the amygdala during morphine self-administration and following acute and chronic morphine treatment by W. Bilecki; J. Rodriguez-Parkitna; B. Ziółkowska; R. Przewłocki (S103).
S.04.05 NMDA receptor blockade increases glutamate efflux in the medial prefrontal cortex: Role of 5-HT2A receptors by I. Ceglia; M. Carli; R.W. Invernizzi (S103-S104).
S.12.01 Neuronal nicotinic receptor subtypes: Perspective on roles in health and disease by J.P. Changeux (S127).
S.12.02 Nicotinic receptor pathologies in human brain by E. Perry (S127-S128).
S.20.04 Involvement of the endogenous opioid system in nicotine dependence by R. Maldonado (S151).
S.20.03 Neuroendocrinological modulation of reward systems and vulnerability by M. Le Moal; M. Marinelli; V. Deroche-Gamonet; P.V. Piazza (S150).
S.20.01 Adrenal & CSF neurosteroids as mediators of HPA axis upregulation and symptom production in premenopausal women with PTSD by A. Rasmusson; A. Guidotti; D. Charney; D. Vojvoda; D. Lipschitz; D. Weisman; J. Krystal (S151-S152).
S.21.03 Developing an animal model for post-traumatic stress disorder by G. Yadid; I. Gispan-Herman; Y. Kesner; Y. Weizman; A. Mendelman; J. Zohar (S152-S153).
S.21.04 Two years after the earthquake: Follow-up of PTSD with and without treatment by K.O. Karamustafaliodlu (S153).
S.20.02 Effects of psychostimulants in the absence of dopamine transporter by B. Giros; E. Morice; M. Nosten-Bertrand (S149-S150).
S.20.01 Neurocircuitry of relapse in cocaine addiction by P. Kalivas (S149).
S.18.05 Drug discovery and mood and anxiety disorders of childhood by J.L. Rapoport (S146).
S.19.02 IGF-1 signaling: Role in neuroprotection and major depression by I. Torres-Aleman; J.L. Trejo; E. Garcia-Galloway; E. Carro (S146-S147).
S.19.03 Trophic factors - role in depressive illness by V. Vaidya (S147-S148).
S.19.05 Perspective role of stem cells application in neuropsychiatric research by E. Sykova (S148-S149).
S.21.05 Ten myths of PTSD by J. Zohar (S153-S154).
S.22.02 Identification of endophenotypes in personality disorders by L. Siever (S154).
S.24.01 New view on the ligand-receptor interaction by J. Bockaert (S159).
S.24.02 Inverse agonism at dopamine receptors by P. Strange (S159-S160).
S.24.03 Agonist trafficking of receptor stimulus and mRNA editing at serotonin2C receptors by W. Clarke; K.A. Berg (S160-S161).
S.24.04 Novel approaches to enhance the detection of receptor constitutive activity and inverse agonists by G. Milligan (S161).
S.23.05 Modeling schizophrenia in animals by B. Lipska (S158-S159).
S.23.04 From the animal models to the clinical treatment modalities in schizophrenia by J. Horacek; V. Bubenikova; M. Kopecek; M. Brunovsky; T. Palenicek; C. Höschl (S158).
S.22.04 Neurobiology of treatment response in affective disorders by M. Alda; P. Grof; G.A. Rouleau; G. Turecki; L.T. Young (S155).
S.22.05 The neurobiology of pleiotropic traits in schizophrenia by P.S. Holzman; S. Matthysse; D.L. Levy (S155-S156).
S.23.01 Animal models and new treatment strategies of anxiety disorders by M. Bourin (S157).
S.23.03 Stress-induced anhedonia in rats: A validated simulation of depression by J.-L. Moreau (S157-S158).
S.18.04 Drug discovery for anxiety disorders by J. Gorman (S145-S146).
S.18.02 The molecular and cellular neurobiology of bipolar disorder by H.K. Manji (S145).
S.14.04 Progression in braim abnormalities and illness severity in schizophrenia by D.H. Mathalon; E.V. Sullivan; K.O. Lim; A. Pfefferbaum (S133-S134).
S.14.02 Progression prior to illness by E. Johnstone; S. Lawrie; D. Job (S133).
S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia by T. Sharma; J.A. Lieberman; J.P. McEvoy; D.O. Perkins; R.M. Hamer; R.B. Zipursky; R.S. Kahn; R.E. Gur; F. Centorrino; I. Glick; A.I. Green; C.B. Nemeroff; A.J. Rothschild; S.M. Strakowski; M. Tohen; G.D. Tollefson (S134-S135).
S.15.02 Cortical and limbic interactions in memory processes by J. Aggleton; T. Jenkins; E. Amin; S. Vann (S135).
S.15.03 Serotoninergic receptor subtypes in cognition by M.C. Buhot; M. Wolff; L. Segu (S135-S136).
S.13.04 Pregabalin: A mechanistically and therapeutically novel anxiolytic by A. Pande (S132-S133).
S.13.02 Anxiolytic-like effects of substance P (NK1 receptor) antagonists (SPAs) in preclinical assays by N. Rupniak (S131-S132).
S.12.03 Physiological regulation of α7 nicotinic receptor activity by endogenous levels of the brain metabolite kynurenic acid: Clinical implications by R. Schwarcz; E.F.R. Pereira; M. Alkondon; L.E.F. Almeida; W.P. Fawcett; W.R. Randall; P. Guidetti; M.T. Sapko; P. Yu; D.A. Tagle; E.X. Albuquerque (S128).
S.12.04 α7 Nicotinic acetylcholine receptors: Neuropsychopharmacological significance by T.H. Svensson (S128-S129).
S.12.05 Treating the cognitive symptoms of Alzheimer's disease with nicotinic a-7 receptor agonists by A.J. Cross (S129-S130).
S.13.01 CRF1 antagonists for anxiety by E. Zorrilla; E. Fekete; B.J. Mason; P. Wirsching; K.D. Janda; G.F. Koob (S130-S131).
S.15.04 Role of central CRF and NPY receptors in the autonomic expression of conditioned fear by O. Stiedl; M. Meyer (S136-S137).
S.15.05 Hippocampal neuropeptides in learning and memory: Implications for cognitive dysfunction and aging by S.O. Ögren; A. Kuzmin; J. Kehr; L. Terenius; J. Sandin (S137-S138).
S.17.03 Gender, age and genetic polymorphism and the response to antidepressant treatment by P.R. Joyce (S143).
S.17.04 Physical treatment of refractory depression in old age by C. Katona (S143-S144).
S.17.05 Treatment of depression in the cognitively impaired elderly by I. Karlsson (S144-S145).
S.18.01 Schizophrenia: Effects of aging on cognition by K. Davis; D. Stewart; J. Friedman; M. Buchsbaum; P. Harvey; P. Hof; J. Buxbaum; V. Haroutunian (S145).
S.17.01 Antidepressant treatment of depression in adolescence by G. Emslie (S143).
S.16.05 Interactions of orexins and leptin with hypothalamic neurons involved in satiety by B. Meister; M. Collin; M. Bäckberg (S142).
S.16.01 Hypocretins and histamine in the physiology and pathology of vigilance states by M. Pretl; S. Nishino; E. Mignot (S138-S139).
S.16.02 Histamine and orexin neurons: Synergistic and complementary regulation on the sleep-wake cycle? by J.-S. Lin (S139-S140).
S.16.03 Histaminergic neurons, attention and learning by P. Blandina; M.B. Passani (S140-S141).
S.16.04 Histamine H3-receptor ligands: Effects of inverse agonists and protean ligands by J.M. Arrang; S. Morisset; A. Rouleau; F. Gbahou; X. Ligneau; J. Tardivel-Lacombe; H. Stark; W. Schunack; C.R. Ganellin; J.-C. Schwartz (S141).
P.1.085 The effect of bupropion on the activity of dopamine transporter in depression — preliminary results by Z. Szabo; M. Argyelan; B. Kanyo; A. Juhasz; Z.S. Kovacs; L. Pavics; Z. Janka (S210).
P.1.086 R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety by C. Sánchez; E. Bien; P. Gruca (S211).
P.1.218 Previous episode burden and response to lithium and lamotrigine in bipolar I disorder by M. Frye; E. Vieta; T. Ketter; J.F. Goldberg; Z. Antonijevic; J. Calabrese (S267).
P.1.217 Predictors of response to lithium and lamotrigine prophylaxis in bipolar I disorder by T. Ketter; C. Bowden; E. Vieta; J.F. Goldberg; Z. Antonijevic; R. Leadbetter (S267).
P.1.219 Role of estrogens in antidepressive effects of venlafaxine by K. Kus; E. Nowakowska; A. Lewandowska (S267).
P.1.220 Influence of α2-adrenoceptor blockade upon the antidepressant profiles of monoamine reuptake inhibitors: A combined neurochemical and behavioural analysis by M.J. Brocco; A. Gobert; A. Dekeyne; M.J. Millan (S268).
P.1.221 Actions of the selective melanin concentrating hormone1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic activity in rodents by M.J. Millan; A. Dekeyne; A. Gobert; B. Di Cara; V. Audinot; D. Cussac; J.-C. Ortuno; J.-L. Fauchère; J.-A. Boutin; M.J. Brocco (S268).
P.1.216 Lamotrigine but not lithium prevents or delays depressive episodes in bipolar I disorder by L. Yatham; G. Goodwin; C. Bowden; J. Calabrese; R. White; R. Leadbetter (S266-S267).
P.1.215 Atypical antipsychotics exhibit superior efficacy in bipolar mania: Results from a meta-analysis by M. Jones; S.C. Martin; G. Papadopoulos (S266).
P.1.211 Burden of manic vs depressive symptoms in subjects with bipolar disorder by R. Hirschfeld; J. Calabrese; M. Frye; M. Reed; K. Wagner (S264-S265).
P.1.212 Effects of lithium and lamotrigine on body weight after 18 months in bipolar I disorder by J. Calabrese; A.H. Young; C. Bowden; Z. Antonijevic; G. Evoniuk (S265).
P.1.213 Safety and tolerability of lamotrigine in bipolar I disorder by E. Vieta; A. Young; M. Berk; G. Asnis; J. Calabrese; G. Sachs; C. Bowden (S265).
P.1.214 Lamotrigine controls bipolar depression without destabilising mood: An analysis of data from 8 placebo-controlled trials by H. Grunze; J. Calabrese; L. Yatham; T. Suppes; S. McElroy; J.F. Goldberg; C. Bowden (S265-S266).
P.1.222 NK1 receptors in human blood lymphocytes and granulocytes by S. Baroni; I. Masala; L. Giusti; L. Betti; G. Giannaccini; D. Marazziti (S269).
P.1.223 In vitro neuro-immunomodulator induced postreceptor changes in immune system and brain by F. Kovářů; H. Kovářů; A. Fišerová; V. Lisá; P. Zelníčková (S269).
P.1.230 Paroxetine improves general somatic symptoms associated with depression by D. Duff; J. Christie (S272-S273).
P.1.231 The brain-derived neurotrophic factor (BDNF) in bipolar affective disorder: A case-control association study by P. Oswald; D. Souery; J. Del-Favero; C. Van Broeckhoven; J. Mendlewicz (S273).
P.1.232 Menopausal depression: Comparing HRT and HRT plus fluoxetine by P. Liu; Q. Yu; W.P. Bai; F.F. He; W. Shi; Y.Y. Wu; D.J. He; J.H. Xiao; Y. Zheng; Q.P. Liao (S273-S274).
P.1.233 Effects of paroxetine and venlafaxine-XP on heart rate variability in depression by L. Watkins; J.R.T. Davidson; K.M. Connor; K.L. Beebe; S. Krulewicz; K. Abraham; W. Zhang; M. Owens; C.B. Nemeroff (S274).
P.1.229 Paroxetine improves somatic pain associated with physical illness in patients with and without comorbid depressive or anxiety disorders by D. Duff; E. Dubé (S272).
P.1.228 Old vs. new antidepressants following ECT by G. Papadimitriou; I.M. Zervas; M.I. Andreadaki; K. Psarros; K. Kontoangelos; C. Dimitrakopoulos; N. Vaidakis; Y. Papakostas (S272).
P.1.224 Transmembrane cell signalling influenced by fluoxetine and adenosine receptor agonist in C6 glioma- and natural killer (NK) cells by H. Kovářů; A. Fiserová; F. Kovářů; I. Malbohan; V. Lisá (S270).
P.1.225 High- and low- affinity binding (affinity-modulation) of S-citalopram binding to the human 5-HT transporter. Importance of single amino acid substitutions in 20 positions of presumed importance by P. Plenge; O. Wiborg (S270).
P.1.226 Release of serotonin and serotonin receptors in the effects of antidepressants by K. Pruus; R. Rudissaar; A. Vaarmann; L. Allikmets (S271).
P.1.227 Anxiety in depression and antidepressants by L. Allikmets; A. Vaarmann; V. Matto (S271).
P.1.210 Concomitant use of lamotrigine and valproate in bipolar I disorder by C. Bowden; J. Calabrese; G. Sachs; G. Evoniuk (S264).
P.1.209 A comparison of remission rates based on HAM-D17 and the HAM-D subscales using MMRM and LOCF method for modeling the missing data by A.R. Entsuah; J. Zhang (S263-S264).
P.1.193 Thyroid auto-antibodies in bipolar affective disorder: Is there a link with lithium treatment? by E. Palazidou; S. Bhandari; D. Samellas; M. Lai; M. Botazzo (S257).
P.1.192 Influence of serotonin selective re-uptake inhibitors on the immune system in clinic and experiment by S. Ivanova; T. Vetlugina; N. Kornetov (S256).
P.1.194 The down-regulation of preprotachykinin A mRNA in the amygdala of subjects affected by mood disorders and schizophrenia does not reflect a change in 3H-SP receptor binding sites by L. Caberlotto; S. Melotto; M. Corsi; R. Carletti (S257).
P.1.195 Effect of CRF1 receptor blockade on rat exploratory behaviour and AP-2 transcription factors in the locus coeruleus region: Important environmental and individual variables by J. Harro; T. Mällo; C. Berggård; M. Eller; L. Oreland (S257-S258).
P.1.196 Effects of bupropion SR on body weight and depressive symptoms in obese patients treated for 50 weeks by E. Goodale; P. Bradley; B. Haight; V. Foster; N. Richard; J. Modell (S258).
P.1.191 No clinically significant weight changes associated with long-term oxcarbazepine treatment by H. Grunze; E. Severus; F. Martenyi; N. Sfikas (S256).
P.1.190 Prevalence and management of depression with painful physical symptoms in a Canadian claims database by J. Hopkins; A.W. Gilsenan; P. Corey-Lisle; C.J. Longo; J. Raskin (S255-S256).
P.1.186 Assessment of sexual dysfunction in depressive patients treated with sertraline by C. Tudor; G. Grigorescu; R. Ciurea; M.D. Gheorghe (S253-S254).
P.1.187 Chronic corticosterone attenuates 5-HT1A-mediated but not GABA-mediated inhibition of rat dorsal raphe neurones by C.D. Ingram; S.E. Gartside; M.M. Leitch; G.F. Fairchild (S254).
P.1.188 Improvement in fatigue with venlafaxine in patients with depression by R. Mallick; H.F. Zhang; G. Wan (S254).
P.1.189 Venlafaxine and SSRIs: Pooled remission analysis by C.B. Nemeroff; A.R. Entsuah; L. Willard; M. Demitrack; M. Thase (S255).
P.1.197 Long-term treatment with bupropion SR effectively prevents the relapse and recurrence of depression by E. Goodale; K. Weihs; J. Ascher; N. Richard; A. Metz (S258-S259).
P.1.198 Follow-up of patients with major depression treated with intravenous mirtazapine by A. Konstantinidis; J. Ptak-Butta; J. Stastny; D. Winkler; E. Pjrek; C. Barnas; A. Neumeister; S. Kasper (S259).
P.1.205 The role of galanin/5-HT1A receptors interaction on attenuation of basal and antidepressant drug-induced increase of extracellular 5-HT levels in the rat hippocampus by J. Kehr; S. Yoshitake; M. Yamaguchi; S.O. Ögren; T. Yoshitake (S262).
P.1.206 Patterns of weight gain in bipolar patients treated with olanzapine or divalproex by R. Baker; E. Brown; L. Schuh; S. Dando (S262).
P.1.207 Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder by R. Bielski; D. Ventura; C. Chang; A. Korotzer (S263).
P.1.208 The direct health care cost of depressive disorders in the United States in 2000 by P.E. Greenberg; R. Kessler; H.G. Birnbaum; E. Moyneur; S.A. Leong; S.W. Low; P.A. Berglund; P.K. Corey-Lisle (S263).
P.1.204 Duloxetine vs placebo in the prevention of relapse of major depressive disorder by M. Detke; I. Gilaberte; D. Perahia; F. Wang; R. McNamara; P. Tran; C. Miner; S.A. Montgomery (S261-S262).
P.1.203 Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK by L. McGarry; A.P. Bird; D. Thompson; J. Cookson; S.C. Martin; M.C. Weinstein (S261).
P.1.199 Remission rates following therapy with bupropion or selective serotonin reuptake inhibitors by M.E. Thase; Y. Wang; N. Richard; M. Mitton; B. Haight; E. Goodale (S259).
P.1.200 Red blood cell triiodothyronine uptake as membrane parameter of depression by L. Stárková; Z. Fisar; I. Paclt; J. Vevera (S259-S260).
P.1.201 Cost reduction implications of sertraline treatment for depression after acute coronary syndromes by A. Glassman; C. O'Connor; D. Harrison; J.R. Swenson (S260).
P.1.202 Adverse effects of antidepressants and antipsychotics: A comparison between old and new generation drugs in a clinical naturalistic setting by G. Barbato; M. Casiello; G. Muscettola (S260-S261).
P.1.234 Antidepressant profile of the melatonin agonist and 5-HT2C antagonist agomelatine (S 20098). Preclinical studies by L. Lanfumey; P.A. Boyer; M. Hamon; E. Mocaër (S274).
P.1.235 Frequency of bipolar disorder spectrum in patients with first episode of depression and recurrent depression by D. Lojko; A. Suwalska; M. Chlopocka-Wozniak; J.K. Rybakowski (S275).
P.2.025 Growth and sexual maturation during treatment with risperidone by F. Dunbar; V. Kusumakar; D. Daneman; M. Schulz (S289).
P.2.024 BIRD (bipolar disorder retrospective data): Switching antipsychotics in patients with bipolar disorder — reasons and outcome by B. Lepage; R. Hoekstra; H. Morre (S288-S289).
P.2.026 Is the drug-induced parkinsonism related to MRI-evident brain abnormality in psychosis? by N. Maric; M. Jasovic-Gasic; V.R. Paunovic (S289-S290).
P.2.027 The occurence of obsessive compulsive symptoms in clozapine treated schizophrenic patients: Relationship with other clinical features by A.E. Anil Yagcioglu; A. Ertugrul; E. Eni; M.K. Yazici (S290).
P.2.028 Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients by I. Corripio Collado; V. Pérez Solá; M. Ferrer Vinardell; M. Serra Buil; M.J. EscartíXátiva; E. Alvarez Martínez (S290-S291).
P.2.023 Prolactin levels in children after long-term treatment with risperidone by R. Findling; V. Kusumakar; D. Daneman; T. Moshang; G. De Smedt; C. Binder (S288).
P.2.022 Open label study for the effect of amantadine on weight gain induced by olanzapine; an interim analysis by W.M. Bahk; K.U. Lee; J.H. Chae; C.U. Pae; T.Y. Jun; K.S. Kim (S288).
P.2.018 Risperidone in the treatment of acute schizophrenia by T. Raedler; A. Schreiner; D. Naber; K. Wiedemann (S286).
P.2.019 Determinants of quality of life in patients with a first episode of schizophrenia by K. Górna; K. Jaracz; A. Suwalska (S286-S287).
P.2.020 Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia by B. Taneli; K. Alptekin; M. Bilici; S. Birsoz; E. Eker; B. Cosar; E. Goka; E. Goktepe; H. Guz; O. Karamustafalioglu; S. Kultur; B.A. Levent; E. Onder; T. Oral; A. Özsahin; B. Veznedaroglu; S. Yuksel; N. Yurtseven (S287).
P.2.021 Use of quetiapine in psychotic disorders. Evaluation of the effects of the treatment using the drug attitude inventory 30 (DAI-30) by M. Cupillari (S287-S288).
P.2.029 Suicide attempts in schizophrenia: The role of impulsivity and substance abuse by A. Dervaux; F.J. Baylé; X. Laqueille; M.C. Bourdel; J.P. Olié; M.O. Krebs (S291).
P.2.030 Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: A double-blind comparison by J. Svestka; O. Synek; A. Zourkova (S291).
P.2.037 A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for the cognitive impairment of schizophrenia by O. Tugal; K.M. Yazici (S295).
P.2.038 Initial stages of insulin resistance in young antipsychotic-free and not in antipsychotic-naive schizophrenic patients by B. Arranz; R. Dueñas; N. Ramirez; P. Fernandez; S. Sarró; L. San (S295-S296).
P.2.039 Methionine homozygosity at codon 129 in the prion protein is associated with white matter reduction and enlargement of CSF compartments by A. Kirner; E.M. Meisenzahl; I. Giegling; M. Reiser; H.-J. Möller; D. Rujescu (S296).
P.2.040 Size matters: The impact of the volume of the amygdala on its activation during the processing of facial expressions of fear by P. Shaw; K. Kucharska-Pietura; T. Russell; F. Zelaya; E. Amaro; M.L. Phillips; A.S. David (S296).
P.2.036 Polymorphisms of dopamine D2 and D4 receptors genes as predictors of therapeutic response to haloperidol and clozapine by P. Vinuesa Gómez; E. Grasa (S294).
P.2.035 Risperidone versus zuclopentixol in acute psychosis in emergency psychiatry: A prospective naturalistic study by J.E.J.M. Hovens; S. Beijeman; J. Tollenaar; P.J.T. Dries; A.J.M. Loonen (S294).
P.2.031 A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders by J. Svestka; O. Synek; A. Zourkova (S292).
P.2.032 Latency period of risperidone, a study with 123I-IBZM spect by S. Oller; I. Corripio Collado; R. Perez-Egea; V. Pérez Solá; A. Catafau; E. Alvarez (S292-S293).
P.2.033 Quality of life of patients with schizophrenia measured by schizophrenia quality of life scale by A. Suwalska; A. Rajewski; F. Rybakowski; D. Lojko; A. Permoda; J.K. Rybakowski (S293).
P.2.034 A novel fast-disintegrating oral formulation of the atypical antipsychotic resperidone by J. Mintzer; P.H. Lechat; B. Remmerie; E. Mannaert (S293).
P.2.016 Speech perception ability of schizophrenia by S.H. Lee; S.J. Lee; Y.C. Chung (S286).
P.2.015 Atypical antipsychotics: Glutamate, amino acids and monoaminergic parameters by F.M.M.A. Van der Heijden; S. Tuinier; D. Fekkes; A.E.S. Sijben; R.S. Kahn; W.M.A. Verhoeven (S285-S286).
P.1.243 The effect of comorbid anxiety on the clinical presentation and treatment response of major depressive disorder: A 12-month naturalistic study by A.C. Altamura; C. Montresor; D. Salvadori; E. Mundo (S278).
P.1.242 Gender differences in depressive symptoms among college students in Bombay by R.M. Parikh; S.B. Sonawalla; N. Chakraborthy; G. Mehra; S. Dracass; M. Fava (S277-S278).
P.1.245 Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence and treatment response in depression by A.-C. Åkerblad; F. Bengtsson; L. Ekselius; L. Von Knorring (S278-S279).
P.2.001 The effects of antipsychotic agents on sceletal muscle of psychiatric patients as it evidences by their serum creatine kinase activity by I. Reznik; M. Kotler; G. Shaked; A. Weizman; B. Spivak; H.Y. Meltzer (S279).
P.2.002 The neural circuitry of persistent latent inhibition as a model of negative symptoms in schlophrenia by D. Schiller; L. Zuckerman; I. Weiner (S279-S280).
P.1.241 Symptom questionnaire assessment of depressive symptoms among college students by S.B. Sonawalla; Y. Mahal; E. Masson; A. Yeung; T. Petersen; D. Mischoulon; M. Fava (S277).
P.1.240 Proton magnetic resonance spectroscopy in depression: Elevated creatine and unaffected myo-inositol levels in the frontal brain by R. Frey; S. Gruber; L. Reinfried; A. Stadlbauer; V. Mlnarik; S. Kasper; E. Moser (S277).
P.1.236 Moclobemide-amitriptyline combination therapy in treatment-resistant depression by P. Pestality; Ż. Rihmer; H.G. Kiss (S275).
P.1.237 Hypoalbuminemia in patients with major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutrition by K.P. Su; C.C. Chiu; S.Y. Huang (S275-S276).
P.1.238 Maprotiline in the treatment of depression by S. Pejkovska-Dimovska; M.Kaeva Pejkovska; M.Mrga Dimovska; D. Mircevska; V. Videnova (S276).
P.1.239 Lithium and circadian rhythms of moving activity and temperature in rats with lesion of right and left suprachiasmatic nuclei by T. Zamoshchina; M. Meleshko; A. Matveenko (S276-S277).
P.2.003 Cognitive performance and side effects under clozapine and amisulpride treatment in patients with chronic schizophrenia by G. Adler; V. Faude; B. Thebaldi; H. Dressing; F.-X. Eich (S280).
P.2.004 Homocysteine reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia by O. Shumeiko; J. Levine; B.A. Sela; R.H. belmaker (S280-S281).
P.2.011 One year outcome on symptoms, motor side effects and cognition in first episode psychosis: A comparison of two novel antipsychotics by A. Malla; R. Norman; D. Scholten; L. Townsend; R. Manchanda; J. Takhar; R. Haricharan (S284).
P.2.012 Prediction of 1-year outcome with brief psychiatric rating scale at 4th week in patients with schizophrenia by A. Yazici; K. Yazici; A. Kanik; S. Tot; P. Erdem (S284).
P.2.013 The influence of haloperidol on erythrocyte magnesium and plasma electrolytes in schizophrenic patients by M. Nechifor; C. Vaideanu; I. Palamaru; C. Borza (S284-S285).
P.2.014 Neurocognitive function and quality of life in treatment resistant auditory hallucinating patients by S.H. Lee; K.Y. Suh; Y.C. Chung (S285).
P.2.010 Differential involvement of the frontal lobe in patients with schizophrenia and schizotypal disorder by M. Suzuki; S.-Y. Zhou; Y. Kawasaki; H. Hagino; T. Takahashi; S. Nohara; M. Matsui; H. Seto; M. Kurachi (S283-S284).
P.2.009 Antipsychotic-induced hyperprolactinemia during acute treatment with antipsychotics by B.H. Lee; C.S. Han; Y.K. Kim (S283).
P.2.005 Successful use of risperidone in an adult with the pervasive developmental disorder, Asperger's syndrome: a case report by S. Raheja; S. Libretto; I. Singh (S281).
P.2.006 Use and cost patterns of risperidone versus olanzapine for the treatment of schizophrenia: An assessment of medicaid children and adolescents age 5–18 years by D.A. Sclar; T.L. Skaer; L.M. Robison; W.M. Dickson; J.S. Markowitz; C.L. De Vane (S281-S282).
P.2.007 Switching strategies with second generation (atypical) antipsychotics: Case report with clozapine and risperidone by Z. Pavlovic; M. Jovanovic (S282).
P.2.008 Remission of positive symptomatology of a schizophrenic psychosis after the discontinuation of lamotrigine by W. Stuve; A. Wessels; L. Timmerman (S282-S283).
P.1.185 Does pretreatment anxiety or insomnia predict acute response to bupropion SR? by A.J. Rush; R. Schmid; B. Haight; S. Zisook; C. Rockett; T. Carmody (S253).
P.1.184 Tolerability of mirtazapine versus SSRIs in patients with major depression by E. Den Braber; A.J. Schutte; S. Van der Flier (S253).
P.1.119 Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism by F. Benedetti; A. Serretti; L. Mandelli; C. Lorenzi; A. Pirovano; C. Colombo; E. Smeraldi (S225).
P.1.118 Changes in depressive neuropsychological functioning during antidepressant treatment by M. Florita; F. Benedetti; C. Colombo; A. Bernasconi; A. Pontiggia; M. Cigala Fulgosi; B. Barbini; E. Smeraldi (S224-S225).
P.1.120 Glycogen synthase kinase 3-b influences age at onset of bipolar disorder by F. Benedetti; A. Bernasconi; C. Lorenzi; A. Pontiggia; C. Colombo; E. Smeraldi (S225).
P.1.121 Rapid assessment of cognitive distorsions in major depression by M. Cigala Fulgosi; F. Benedetti; M. Florita; C. Colombo; B. Barbini; E. Smeraldi (S225-S226).
P.1.122 Long-term sertraline treatment in children and adolescents with major depressive disorder by M. Rynn; K. Wagner; C. Donnelly; C. Wohlberg (S226).
P.1.117 Morning light therapy as an augmenting strategy of antidepressant treatment by A. Bernasconi; F. Benedetti; C. Colombo; A. Pontiggia; M. Florita; E. Smeraldi (S224).
P.1.116 Phase-response effects of lormetazepam in depressive insomnia by A. Pontiggia; F. Benedetti; E. Smeraldi; A. Bernasconi; M. Florita; C. Colombo; I. Cropanese (S223-S224).
P.1.112 Serum lipids, depression and anhedonia in suicide attempters by K.G. Paplos; V.P. Kontaxakis; B.J. Havaki-Kontaxaki; A.G. Alaveras; M.R. Issidorides; G.N. Christodoulou (S222).
P.1.113 Serum total cholesterol and triglycerides in suicide attempters: Comparison with schizophrenic patients and healthy subjects by V.P. Kontaxakis; K.G. Paplos; B.J. Havaki-Kontaxaki; G.N. Christodoulou (S222).
P.1.114 Effects of sertraline and venlafaxine on serum TNF-α in major depressive disorder by C. Tuglu; H. Kara; O. Caliyurt; E. Vardar; E. Abay (S222-S223).
P.1.115 CLOCK gene and circadian mood fluctuations in bipolar depression by F. Benedetti; A. Serretti; C. Colombo; B. Barbini; C. Lorenzi; E. Campori; E. Smeraldi (S223).
P.1.123 CLOCK gene influences insomnia during antidepressant treatment by F. Benedetti; A. Serretti; C. Cusin; L. Mandelli; A. Pirovano; R. Zanardi; C. Colombo; E. Smeraldi (S226).
P.1.124 Milnacipran in the treatment of adolescent depression or dysthymia by S. Tauscher-Wisniewski; M.H. Friedrich (S226-S227).
P.1.131 Efficacy of reboxetine and amisulpride on cognitive functions in elderly inpatients with major depressive disorder and psychotic features by D. Vasile; R. Ciurea; M.D. Gheorghe (S229-S230).
P.1.132 First signs of improvement with tianeptine in the treatment of depression: An analysis of a double-blind study versus fluoxetine by V. Novotný; F. Faltus (S230).
P.1.133 The use of antidepressants in bipolar depression: A retrospective and naturalistic study by J.M. Montes; A. Asiel; C. Lahera; P. Sopelana; J. Saiz-Ruiz (S230-S231).
P.1.134 Association study of a G-protein beta3 subunit gene polymorphism and major depressive disorders, symptomatology, and treatment response by H.-J. Lee; S.-H. Ryu; M.-S. Lee (S231).
P.1.130 The compounds Org 34517 and Org 34850 are potent antagonists of the glucocorticoid receptor both in vitro and in vivo by F. Thomson; M.W. Craighead; L. Watson; Z. Turnbull; L. McIntosh; M. Speake; A. Hillier; S. Eason; M. Shahid; H.M. Marston; D.R. Hill (S229).
P.1.129 A double blind, randomized, multicentric pilot study comparing differential effects on cognitive functioning in agitated-impulsive depression with two SSRIs by E. Perrin; J. Dalery; M. Faruch; S. Ammar; P. Quintin; D. Gourion; R. Jouvent; S. Dubal (S228-S229).
P.1.125 A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling by J. Calabrese; M. Shelton; D. Rapport; E. Youngstrom; E. Shirley; O. Elhaj; K. Packer; S. Bilali; R. Findling (S227).
P.1.126 Effects of lamotrigine on neurocognitive measures in bipolar I patients by L.N. Yatham; K.H. Davis; A. Khan; L.D. Ginsberg; G.M. Asnis; F.K. Goodwin (S227-S228).
P.1.127 The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline by S. Preskorn; R. Shah; B. Silkey; M. Neff; A. Golbeck; J. Choi (S228).
P.1.128 Dysphoric mania: A controlled study of the benefits of olanzapine combined with valproate or lithium by M. Tohen; R. Baker; E. Brown; L. Schuh; P. Trzepachz; S. Dando (S228).
P.1.111 A steady-state evaluation of the effect of rifampicin on the pharmacokinetics of gepirone ER and metabolites by Y.W.F. Lam; L. Ereshefsky; A. Port; C.J. Timmer; P. Dogterom (S221-S222).
P.1.110 Outcome of bipolar disorders. A naturalistic study by P. Vinuesa (S221).
P.1.094 AZD1134, a high affinity 5-HT1B receptor antagonist activates serotonin turnover and release in guinea pig brain by G.N. Smagin; D. Song; A.J. Cross; L. Mrzljak (S214).
P.1.093 The multi-central clinical study on the efficacy of paroxetine over anxiety symptoms in mixed anxiety-depression by N. Kocabasoglu; A. Corapcioglu; I. Yargic (S213-S214).
P.1.095 Conditional probability of remission at 8 weeks given early global improvement in major depressive disorder (MDD) by M. Fava; T. Burt; E. Batzar; H. Sackeim (S214).
P.1.096 Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator by M. Thase; Y. Lu; M. Joliat; M. Detke (S215).
P.1.097 Escitalopram versus citalopram: More efficacious and well tolerated in long-term treatment of moderately depressed patients by F. Menard; L. Colonna; H.F. Andersen (S215).
P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial by A. Evans; M. Tohen; A. Marneros; C. Bowden; W. Greil; A. Koukopoulis; R.H. Belmaker; T. Jacobs; R. Baker; D. Williamson; M. Dossenbach; G.B. Cassano (S213).
P.1.091 Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial by M. Tohen; C. Bowden; J. Calabrese; J. Chou; T. Jacobs; R. Baker; D. Williamson; A. Evans (S212-S213).
P.1.087 Effect of the SSRI, escitalopram, and non-selective 5-HT reuptake inhibitors in animal models of pain by C. Sánchez (S211).
P.1.088 Interactions between SSRI and flattened glucocorticoid rhythm with respect to 5-HT function: Implications for antidepressant efficacy by S.E. Gartside; M.M. Leitch; A.H. Young (S211-S212).
P.1.089 Analysis of treatment-emergent mania with olanzapine/fluoxetine combination by P. Keck; S. Corya; S. Briggs; M. Case; M. Tohen (S212).
P.1.090 Olanzapine/fluoxetine combination improves long-term quality of life in bipolar depression by M. Tohen; L. Shi; C. Vallarino; V. Prabhakar; R. Juarez; M. Namjoshi (S212).
P.1.098 The S-enantiomer of citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors by O. Wiborg; F. Chen; M.B. Larsen; C. Sánchez (S215-S216).
P.1.099 Antidepressant-like effects of felbamate on locomotor behaviour and leukocyte phagocytosis in rats by J. Pistovcakova; A. Sulcova (S216).
P.1.106 The efficacy and side effect profile of the antidepressants by M. Keresztes-Nagy; I. Kecskés; Z. Rihmer (S219).
P.1.107 Depression and painful physical symptoms in Europe by R. Peveler; A. Garcia-Cebrian; A. Lothgren; P. Ghandi (S219-S220).
P.1.108 Effects of electroconvulsive therapy on urinary metabolites of neurogenic bioamines in depressive patients by T. Turan; S. Keles; E. Esel; F. Narin; C. Kylyc; M. Basturk (S220).
P.1.109 The effects of early maternal separation on pre- and post-synaptic 5-HT1A receptor binding in the rat brain by C. Troakes; S.E. Gartside (S220-S221).
P.1.105 Effects of electroconvulsive therapy on thyroid stimulating hormone response to thyrotropin-releasing hormone in depressive patients by T. Turan; C. Kylyc; E. Esel; M. Kula; S. Keles; M. Basturk (S218-S219).
P.1.104 The effects of dopamine on dorsal raphe 5-HT neuronal firing: In vitro electrophysiological studies by D. Johnson; S.J. Judge; S.E. Gartside; C.D. Ingram (S218).
P.1.100 “Useful” side effect: Result of the good selection by I. Kecskés; M. Keresztes-Nagy; Z. Rihmer (S216).
P.1.101 R-citalopram decreases the association of [3H]-S-citalopram with the human serotonin transporter by an allosteric mechanism by O. Wiborg; C. Sánchez (S217).
P.1.102 Hypercortisolemia-induced hippocampal effects and antidepressant drugs. Preliminary report by D.C.G. Marinescu; L. Mogoanta; T. Udristoiu (S217).
P.1.103 Membrane lipids and serotonin uptake after long-term administration of antidepressants by Z. Fisar; M. Anders; E. Tvrzická; K. Fuksová (S217-S218).
P.1.135 Attention deficit hyperactivity disorder in patients with bipolar disorder by C. Tuglu; L. Tamam; G. Karatas; S. Ozcan (S231).
P.1.136 Pharmacotherapeutic trends of bipolar disorders in Hungary by G. Kovács (S231-S232).
P.1.168 The higher body mass index of Taiwanese adolescent bipolar patients by C.Y. Shang; S.Y. Tsai (S246).
P.1.167 Chronic treatment with fluoxetine produced time realted alterations in opioid, cannabinoid and tirosine hydroxilase gene expression in selected regions of the rat brain by J.M. Oliva; L. Urigüen; S. Pérez-Rial; S. Ortiz; T. Palomo; J. Manzanares (S245-S246).
P.1.169 Bipolar and pregnant? No problem! A clinical evaluation of lithium use during pregnancy by A. Kramer; E.A.M. Knoppert-Van der Klein; I.L. Van Kamp; F.J. Walter; I.M. Van Vliet; F.G. Zitman (S246).
P.1.170 A comparative study of serotonin transporter occupancy: In vivo 5-HT reuptake inhibitory potency and serum concentrations of antidepressants in mice by A.K. Larsen; L.T. Brennum; M. Kreilgaard; C. Sánchez; C. Halldin; P.H. Andersen (S246-S247).
P.1.171 Impairment in major depressive disorder by W. Pitchot; K. Demyttenaere; A. Albert; L. Zhang; P. De Cock (S247).
P.1.166 A double-blind, randomized, steady-state, cross-over evaluation in healthy volunteers of the interaction of gepirone ER and paroxetine by L. Ereshefsky; Y.W.F. Lam; L. Tritsmans; C.J. Timmer; P. Dogterom (S244-S245).
P.1.165 Olanzapine versus risperidone for the treatment of affective symptoms in subjects with intellectual disabilities by P.K. Mölsä (S244).
P.1.161 Electroconvulsive therapy: Influence of the anaesthetic agent by M. García Mahía (S242-S243).
P.1.162 The antiepileptic drug levetiracetam modulates plasma corticosterone levels in two rat models of HPA axis activation by R. Grimée; G. Lorent; Y. Lamberty (S243).
P.1.163 Venlafaxine in inpatients — sustained remission as a treatment goal by V. Korinkova; E. Kolibas; V. Novotný (S243).
P.1.164 Mood disorders and antidepressant treatment of prisoners with a history of self-mutilation by N.P. Lekka; S. Beratis (S243-S244).
P.1.172 Bright light therapy in seasonal affective disorder — does it suffice? by E. Pjrek; D. Winkler; A. Konstantinidis; N. Thierry; A. Heiden; S. Kasper (S247-S248).
P.1.173 Diagnosis of depression by the primary care physician and the patient by K. Demyttenaere; W. Pitchot; A. Albert; L. Zhang; P. De Cock (S248).
P.1.180 Paroxetine improves sleep disturbances associated with major depression by J.R.T. Davidson; J. Christie; D. Duff; E. Dubé (S251).
P.1.181 Sexual function of patients with major depression treated with mirtazapine fast dissolving tablets or sertraline by S. Van der Flier; E. Vester-Blokland (S251-S252).
P.1.182 Mirtazapine versus paroxetine in depressed primary care patients: A randomised, double-blind, 24-week study by A. Wade (S252).
P.1.183 The lateral septum and the central nucleus of the amygdala mediate the antidepressant-like action of the V1b receptor antagonist, SSR149415, in rats by J. Stemmelin; L. Lukovic; C. Transetti; P. Soubrie; G. Griebel (S252).
P.1.179 Factor analysis on onset of therapeutic effect of mirtazapine fast dissolving tablets versus sertraline by A.J. Schutte; E. Vester-Blokland (S251).
P.1.178 Association between the serotonin transporter linked polymorphic region gene (5-HTTLPR) and response to tricyclic antidepressants (TCAs) by E.-M. Tsapakis; S. Checkley; R.W. Kerwin; K.J. Aitchison (S250).
P.1.174 Assessment of cerebral regions associated with sexual arousal in depressive women by using functional magnetic resonance imaging by J.-C. Yang; M.S. Lee; J.S. Yoon; H.K. Kang; G.W. Jeong; H.J. Kim; S.J. Eun; T.J. Zheng (S248-S249).
P.1.175 The effects of lithium treatment on bone mineral density of bipolar patients by Y. Eren; M. Yyldyz; Y. Çivi; D. Gündodar; R. Özcankaya (S249).
P.1.176 The effect of depression on life quality of patients with type II diabetes mellitus by Y. Eren; Ö. Erdi; Ö. Erdi; R. Özcankaya; D. Gündodar (S249).
P.1.177 Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression by S. Corya; P. Keck; J. Calabrese; S. Andersen; M. Gillig; R. Baker; M. Tohen (S250).
P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60–120 mg QD) by M. Wohlreich (S242).
P.1.159 A multi-dimensional approach to major depression by G. Tacchini; S. Fumagalli; O. Fusi; A.C. Altamura (S241-S242).
P.1.143 Simplified citalopram challenge test as a potentional depression marker by J. Svarc (S234-S235).
P.1.144 Amitriptiline mechanism of action may relate to oleate activated phospholipase D inhibition by M. Krzystanek; I. Krupka-Matuszczyk; H.I. Trzeciak; E. Krzystanek (S235).
P.1.145 Efficacy and safety of mirtazapine in elderly depressed patients by B.K. Yeon; B.H. Oh; M.S. Lee; C.W. Lee; B.S. Gee; S.G. Ryu (S235-S236).
P.1.146 Sertraline versus amitriptyline in the treatment of in-patients with acute depressive disorders by J. Svestka; A. Zourkova; O. Synek; E. Ceskova (S236).
P.1.142 Obsessive-compulsive symptoms in mania by M. Raja; A. Azzoni (S234).
P.1.141 Physical activity as a protection against depressive symptoms in early adolescence by G. Morken; A.M. Sund (S234).
P.1.137 Autoimmune thyroiditis (AIT) and affective disorders — a prospective pilot study by D. Degner; S. Bleich; M. Haust; I. Zerr; E. Rüther; J. Meller (S232).
P.1.138 Eye movement disturbances in patients with bipolar illness by A. Kepa; A. Borkowska; J. Hauser; A. Leszczynska; M. Kosmowska; J.K. Rybakowski (S232-S233).
P.1.139 How accurate can we predict antidepressant-induced hypomania? by O. Zivanovic; L. Borisev (S233).
P.1.140 The GAMIAN-Europe BEAM survey, Dutch part: Information on current treatment of bipolar disorder generated by a patient questionnaire by E.M. Van Gent; J. Bonte (S233).
P.1.147 Phenotype dynamics and its clinical correlates in patients treated by paroxetine by A. Zourkova; E. Hadasova; L. Pilarova; O. Kuliskova; M. Robes (S237).
P.1.148 The novel antidepressant agomelatine (S 20098) acts independently of 5-HT1A receptors in the rat by L. Lanfumey; N. Hanoun; P.A. Boyer; E. Mocaër; M. Hamon (S237).
P.1.155 Remission of early responders in patients with major depression treated with mirtazapine by H.S. Suh; C.H. Kim; H.S. Lee; M.S. Koo (S240).
P.1.156 An analysis of the treatment patterns of bipolar disorder in the UK using a general practitioner database by M. O'Leary; K. Davis; A. Krishnan (S240).
P.1.157 Effect of the CYP3A4 inhibitor ketoconazol on the pharmacokinetics of mirtazapine in healthy volunteers by P. Baumann; M.W. Van den Heuvel; J.M.A. Sitsen; C.B. Eap; P.A.M. Peeters (S241).
P.1.158 SSRIs increase 5-HT2A receptor binding in depressed patients: A SPECT study by H. D'haenen; A. Schins (S241).
P.1.154 Association study on the genetic polymorphism of the biogenic amine transporter gene family and antidepressant responsiveness in Korean depressed patients by D.K. Kim; Y.-A. Kwon; S.W. Lim; H. Kim (S239-S240).
P.1.153 Serotonin transporter gene polymorphisms in depression by D.K. Kim; S.W. Lim; H. Kim (S239).
P.1.149 Escitalopram for treatment of depression and anxiety disorder in adult outpatients by N. Klein; G. Wiesegger; D. Winkler; T. Attarbaschi; N. Mossaheb; S. Kasper; J. Tauscher (S237-S238).
P.1.150 Side effects causing dropout in outpatients treated with antidepressants by Ö. Uzun; A. Cansever; A. Özsahin; A. Ateh; U. Çalyhkan (S238).
P.1.151 The effect of chronic lithium and lithium withdrawal on dopaminergic function by L. Ferrie; A.H. Young; r. McQuade (S238-S239).
P.1.152 An appropriate strategy for screening antidepressant drugs using the mouse forced swimming test and the tail suspension test by F. Chenu; B.A. Nic Dhonnchadha; N. Ripoll; D.J.P. David; M. Hascoët; M. Bourin (S239).
L.01 Novel strategies for treatment of schizophrenia and Parkinson's disease. Focus on receptor-receptor interactions in the basal ganglia by K. Fuxe; S. Ferré; A. Woods; C. Lluis; R. Franco; L. Agnati (S93-S94).